


KRYPTON 85  
A REVIEW of the LITERATURE  
and  
an ANALYSIS of  
RADIATION HAZARDS



ENVIRONMENTAL PROTECTION AGENCY  
Office of Research and Monitoring

ENVIRONMENTAL PROTECTION AGENCY  
OFFICE OF RESEARCH AND MONITORING  
TWINBROOK RESEARCH LABORATORY

The technical publications issued by the Twinbrook Research Laboratory report results of intramural and contractor projects. A limited number of the reports are distributed to regional, state, and local radiological health agencies, to universities and libraries, to other government and private agencies, and to interested individuals.

Twinbrook Research Laboratory technical reports are generally available from the National Technical Information Service, Springfield, Virginia 22151. Microfiche copies are \$0.95 and paper copies are \$3.00 unless otherwise noted.

**KRYPTON 85**  
**A REVIEW of the LITERATURE**  
**and**  
**an ANALYSIS of**  
**RADIATION HAZARDS**

William P. Kirk

Eastern Environmental Radiation Laboratory  
P.O. Box 61  
Montgomery, Alabama 36101

JAN 1972



ENVIRONMENTAL PROTECTION AGENCY  
Office of Research and Monitoring  
Washington, D.C. 20460

## FOREWORD

Krypton-85 is a long-lived, fission-product, noble gas which is released to the atmosphere in large quantities by the nuclear industry, primarily by reactor fuel reprocessing plants. Although development of the technology needed to collect the krypton-85 at reprocessing facilities is nearing fruition, the atmospheric build-up of krypton-85 is expected to continue for some time due to the rapid growth of the nuclear power industry. The present atmospheric inventory of about 60 megacuries is more than twice the inventory of a decade ago and is increasing rapidly. The distribution of  $^{85}\text{Kr}$  is essentially global once it is released, with radioactive decay ( $T_{1/2} = 10.76 \text{ yr}$ ) being the only important removal mechanism.

The current permissible  $^{85}\text{Kr}$  concentration values are based on calculations and extrapolations rather than on the results of direct experimental investigation of the effects of  $^{85}\text{Kr}$  on living animals. Thorough investigation of the physiological behavior and effects of  $^{85}\text{Kr}$  in living animals is, therefore, imperative. This report summarizes the background information upon which studies of this type, being undertaken at the Eastern Environmental Radiation Laboratory, Montgomery, Alabama, are based. Additional information is sought on a continuing basis, and the interest and comments of all those concerned with radiological and environmental health are solicited.



William A. Mills, Ph.D.  
Director  
Twinbrook Research Laboratory

# TABLE OF CONTENTS

Foreword . . . . .	<i>iii</i>
Abstract . . . . .	<i>vi</i>
Acknowledgments. . . . .	<i>vii</i>
INTRODUCTION . . . . .	1
BACKGROUND INFORMATION . . . . .	1
Characteristics . . . . .	1
Chemical . . . . .	1
Physical Data . . . . .	2
Radiological Data . . . . .	3
Source Information . . . . .	3
Present (MPC) <sub>a</sub> and Rationale . . . . .	4
<sup>85</sup> KR AS AN ENVIRONMENTAL CONTAMINANT . . . . .	5
How and When <sup>85</sup> Kr is Released to the Environment . . . . .	5
Distribution of <sup>85</sup> Kr . . . . .	7
Worldwide Concentration and Dose Estimates . . . . .	7
<sup>85</sup> Kr Concentrations and Doses Near Reprocessing Facilities . . . . .	10
Removal of <sup>85</sup> Kr from Process Streams Before Release to the Atmosphere . . . . .	11
USES OF KRYPTON 85 . . . . .	13
Medicine and Closely Allied Areas . . . . .	13
Non-medical Uses of <sup>85</sup> Kr . . . . .	14
RADIATION HAZARDS ASSOCIATED WITH <sup>85</sup> KR . . . . .	15
Skin Dose . . . . .	15
Dose in the Body . . . . .	16
Dose from <sup>85</sup> Kr Outside the Body . . . . .	16
Dose from <sup>85</sup> Kr Contained in the Body . . . . .	16
Doses to Skin, Whole Body, and Male Gonads at Unrestricted (MPC) <sub>a</sub> . . . . .	17
Skin . . . . .	17
Gonads (Male) . . . . .	17
Whole Body . . . . .	17
Other Dose Calculations . . . . .	18
Comparison of Doses Delivered at the Unrestricted (MPC) <sub>a</sub> With Permitted Doses . . . . .	19
Unexplained Phenomena Involving Noble Gases . . . . .	21

SAMPLING AND ANALYSIS OF $^{85}\text{Kr}$ . . . . .	22
Detection and Counting . . . . .	22
General . . . . .	22
Detectors Used . . . . .	22
GM Counters . . . . .	22
Internal Ionization and Proportional Counters . . . . .	23
Scintillation Counters . . . . .	23
Gamma Scintillation . . . . .	23
Beta Scintillation . . . . .	23
Semi-Conductor Detectors . . . . .	25
Calibration and Standardization . . . . .	26
Sampling and Sample Preparation . . . . .	26
SUMMARY . . . . .	27
REFERENCES . . . . .	29

## TABLES

1. Annual Dose from Immersion in Air with a Concentration $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$ . . . . .	18
2. Summary of Dose Limits for Individuals . . . . .	19
3. Minimum Detectable $^{85}\text{Kr}$ Concentrations for Calibrated External Beta Counters. . . . .	24
4. Minimum Detectable Concentrations of $^{85}\text{Kr}$ in Ionization Chambers . . . . .	25
A-1. Solubility Coefficients for $^{85}\text{Kr}$ in Various Solvents . . . . .	50

## FIGURES

1. Scheme of Hydroquinone Clathrate . . . . .	2
2. Estimated Krypton-85 Concentrations in Air, 1970-2060 . . . . .	6
3. Estimated Annual Doses from Krypton-85, 1970-2060 . . . . .	7
4. Comparison of Estimated $^{85}\text{Kr}$ Concentration in Air 1970-2060, with Measurements through 1970 . . . . .	8
5. Krypton-85 Concentration in Air . . . . .	9
6. Estimations of Annual Dose Rates from $^{85}\text{Kr}$ . . . . .	10
7. Comparison of Estimations of Annual Dose Rates from $^{85}\text{Kr}$ . . . . .	20
A-1. Hypothetical $^{85}\text{Kr}$ Saturation and Desaturation Curves for Standard Man . . . . .	55
A-2. Experimental $^{85}\text{Kr}$ Desaturation Curves in Rat   Short Exposure . . . . .	56
A-3. Experimental $^{85}\text{Kr}$ Desaturation Curves in Rat - Long Exposure . . . . .	56

## APPENDIX A

Absorption of Kr into the Body . . . . .	47
Appendix Reference . . . . .	57

## ABSTRACT

This review summarizes most of the existing information on  $^{85}\text{Kr}$ . Major subject areas covered are (1) physical, chemical and radiological data, (2) maximum permissible concentration in air  $(\text{MPC})_a$  and its rationale, (3) source data, (4) atmospheric concentrations and dose estimates near reprocessing facilities and worldwide, (5) proposed control methods, (6) uses in science, especially medicine, and industry, (7) calculations of dose to various organs and their relationship to the  $(\text{MPC})_a$ , (8) unexplained noble gas phenomena, and (9) methods of sampling and analysis.

The *in vivo* internal behavior of  $^{85}\text{Kr}$  is discussed in detail in appendix A and preliminary desaturation curves obtained with rats are presented. The review includes 280 references.

## ACKNOWLEDGMENTS

This report was written as part of the Ph.D. dissertation in the Department of Radiation Biology, School of Medicine and Dentistry, University of Rochester, Rochester, New York.

The author wishes to especially thank his faculty advisor, Donald A. Morken, Ph.D., for his support and assistance in its evolution and a host of University Librarians for their assistance in collecting the mass of reference material used.



## INTRODUCTION

Krypton 85 is one of the most important gaseous contaminants produced in nuclear fission. Public health concern has centered on its release to the atmosphere during reactor operations and especially during fuel reprocessing. Rapid expansion of the medical, scientific and industrial uses of  $^{85}\text{Kr}$  have made it of practical importance to the health physicist. The literature on  $^{85}\text{Kr}$  is singularly parochial and is spread through many disciplines with little cross-referencing. This report reviews much of this literature and provides general information and references regarding  $^{85}\text{Kr}$ . The reference list is not complete, particularly with respect to some government reports from this country and abroad which are difficult to locate and obtain, and to the rapidly proliferating field of medical uses. This report specifically attempts to:

1. Furnish physical, chemical, and radiological data on  $^{85}\text{Kr}$
2. Review sources, yields, and amounts released in different operations
3. Review the current maximum permissible concentrations in air (MPC)<sub>a</sub> values and their rationale
4. Review the status of  $^{85}\text{Kr}$  as an environmental contaminant and proposed methods of control
5. Enumerate a number of uses for  $^{85}\text{Kr}$  in science, especially medicine and industry
6. Evaluate the radiation hazard associated with  $^{85}\text{Kr}$  and relate it to existing limits
7. Review methods that have been successfully used to collect, prepare and analyze  $^{85}\text{Kr}$ .

## BACKGROUND INFORMATION

### CHARACTERISTICS

#### CHEMICAL

The family of noble gases that includes krypton has been traditionally regarded as chemically inert. Modern studies have revealed, however, that the more polarizable members can participate in ionic or covalent bonding, under appropriate conditions, with highly<sub>1</sub> reactive elements such as fluorine and oxygen (1,2) and that clathrates<sup>1</sup> can be formed with water

---

<sup>1</sup>A clathrate is a solid that incorporates a gas into voids in its crystal structure. See figure 1.

(hydrates) and a number of organic solvents (1,3,4,5). Most of these compounds dissociate at physiological temperatures but some of the organic clathrates, including hydroquinones, are relatively stable at normal temperatures (4,5). The structure of hydroquinone clathrate is shown in figure 1. Several authors have postulated clathrate formation involving side chains on body proteins to explain the observed narcotic effects of xenon, the most reactive noble gas, and other gases that produce similar reactions (3,6,7,8). The noble gases are highly soluble in non-polar solvents, including body lipids, with solubility decreasing in order of radon, xenon, krypton, argon, neon, and helium (9). Solubility is discussed in more detail in Appendix A.




Figure 1. Scheme of hydroquinone clathrate, after Balek (5).

#### PHYSICAL DATA

*Cryogenic Reference Data* (10) and the *Radiological Health Handbook* (11) give the following information concerning krypton:

Atomic weight (naturally occurring) = 83.9  
 Melting point =  $-157.2^{\circ}\text{C}$  ( $-250.9^{\circ}\text{F}$ )  
 Boiling point =  $-153.3^{\circ}\text{C}$  ( $-244^{\circ}\text{F}$ )  
 Triple point =  $-157.2^{\circ}\text{C}$ , 548.2 mm Hg ( $-251^{\circ}\text{F}$  and 10.6 PSIA)  
 Critical point =  $-63.8^{\circ}\text{C}$  ( $-82.8^{\circ}\text{F}$ ) and 41,165 mm Hg (796 PSIA)

One kg of natural krypton occupies a volume of 287.45 liters at NTP ( $20^{\circ}\text{C}$ , 760 mm Hg) or 266.79 liters at STP ( $0^{\circ}\text{C}$  760 mm Hg).

The naturally occurring isotopes of krypton and their percentages of natural abundance are  $^{78}\text{Kr}$  (0.35%),  $^{80}\text{Kr}$  (2.27%),  $^{82}\text{Kr}$  (11.56%),  $^{83}\text{Kr}$  (11.55%),  $^{84}\text{Kr}$  (56.9%) and  $^{86}\text{Kr}$  (17.37%). Radioactive isotopes of krypton include 74-77, 79, 79m, 81, 81m, 83m, 85, 85m, 87-95, and 97.

#### RADIOLOGICAL DATA

The following data are given by the *Radiological Health Handbook* (11) or the *National Bureau of Standards* (12) for  $^{85}\text{Kr}$ :

Half life = 10.76 years

Emissions: Beta;  $E_{\text{max}} = 0.672\text{ MeV}$ ,  $\bar{E} = 0.249\text{ MeV}$ , frequency = 99.59% (11) or 99.56% (12). A 0.16 MeV  $E_{\text{max}}$  beta, which is usually ignored in calculations, is associated with the 0.514 MeV gamma.

Gamma;  $E = 0.514\text{ MeV}$ , Branching ratio = 0.41% (11) or 0.443% (12).

Revisions in the published values have occurred and are the cause of most differences in doses or dose rates calculated by different authors.

#### SOURCE INFORMATION

The amount of  $^{85}\text{Kr}$  formed depends on a number of factors including the specific heavy nuclei being fissioned, the neutron flux, the neutron energy spectrum, and the irradiation time. The amount present at analysis will be determined by the foregoing factors and the time that has elapsed between irradiation and analysis, or cooling time. The general expression for the amount of  $^{85}\text{Kr}$  present in a reactor or fuel element is:

$$C = 8.4 \times 10^5 P_i Y_i (1 - e^{-\lambda T}) e^{-\lambda t} \quad (13)$$

where: C = curies of  $^{85}\text{Kr}$  present

$P_i$  = total nuclear power supplied by reactor system i, MW

$Y_i$  = fission yield of system for  $^{85}\text{Kr}$

$\lambda$  = decay constant for  $^{85}\text{Kr} = 1.76 \times 10^{-4}\text{ days}^{-1}$

T = irradiation time (days)

t = cooling time (days)

Various estimates of  $Y_i$  in the literature include:

$$\begin{aligned} Y_i ({}^{235}\text{U}, \text{thermal neutrons}) &= 0.00293 (14); 0.00273 (15); 0.00306 (16) \\ Y_i ({}^{235}\text{U}, \text{fission neutrons}) &= 0.00310 (16) \\ Y_i ({}^{239}\text{Pu}, \text{thermal neutrons}) &= 0.00099 (15); 0.0012 (16) \\ Y_i ({}^{239}\text{Pu}, \text{fission neutrons}) &= 0.001446 (16) \\ Y_i ({}^{239}\text{Pu}, \text{fast neutrons}) &= 0.00076 (17) \\ Y_i ({}^{233}\text{U}, \text{thermal neutrons}) &= 0.0058 (14) \end{aligned}$$

An estimate of average  ${}^{85}\text{Kr}$  production is 0.2 kCi per megawatt of energy produced (1 year operation, 1 day cooling) (18).

#### PRESENT $(\text{MPC})_a$ VALUES AND RATIONALE

The presently accepted maximum permissible concentrations in air for  ${}^{85}\text{Kr}$ , as established by the AEC (19), NCRP (20), and ICRP (21), are  $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$  ( $3 \times 10^5 \text{ pCi}/\text{m}^3$ ) for unrestricted areas,  $10^{-5} \mu\text{Ci}/\text{cm}^3$  ( $10^7 \text{ pCi}/\text{m}^3$ ) for occupational exposure for 40 hours weekly, and  $3 \times 10^{-6} \mu\text{Ci}/\text{cm}^3$  ( $3 \times 10^6 \text{ pCi}/\text{m}^3$ ) for occupational exposure for a 168-hour week.

The  $(\text{MPC})_a$  values and the estimated doses in most published projections are based on calculations of the external dose received by a person standing in an infinite hemispheric cloud of the radioactive gas. This is standard procedure for noble gases.<sup>2</sup> Internal absorption or concentration is not considered. The occupational  $(\text{MPC})_a$  for a 40-hour week is calculated from the formula:

$$(\text{MPC})_a = \frac{0.024 R}{\Sigma(E)} \rho_a (\rho_a/\rho_t) \mu\text{Ci}/\text{cm}^3$$

where:  $R$  = dose permitted in one week (rem)

$\rho_a$  = density of air ( $0.00129 \text{ g}/\text{cm}^3$ )

$\rho_a/\rho_t$  = stopping power of air relative to tissue  
(=  $1/1.13$  for beta and secondary electrons produced by x or  $\gamma$  radiation)

$\Sigma(E)$  = effective energy per disintegration (MeV)

Two sub-categories are recognized. If the radiation emitted is gamma radiation or beta radiation with maximum energy equal to or greater than 0.1 MeV, the critical organ is taken to be the whole body and  $R$  is set at 0.1 rem/week. If the emissions are alpha particles or beta particles with maximum energy less than 0.1 MeV, the critical organ is considered to be to the skin of the whole body and  $R$  is taken to be 0.6 rem/week. Krypton 85 falls in the former group and is considered to deliver its dose to the whole body even though the deposition of energy from externally incident 0.672 MeV beta particles will be deposited within about a 2 mm depth in tissue (11,22) with the average penetration being slightly greater than 0.2 mm (22). The overall effect is to overestimate the dose

<sup>2</sup>The lung is used as the critical organ for radon in equilibrium with its daughters.

actually delivered to the whole body. This will be discussed in detail later. It has been recognized that the MPC values in use are conservative (23,24), and the next issue of the ICRP Recommendations is expected to increase them by a factor of about 5 (24).

## $^{85}\text{Kr}$ AS AN ENVIRONMENTAL CONTAMINANT

### HOW AND WHEN $^{85}\text{Kr}$ IS RELEASED TO THE ENVIRONMENT

Krypton 85 is produced by nuclear explosions and continuously during reactor operations. It has been concluded (25,26), from considerations of experimentally determined air concentrations versus total weapons yield, that most of the  $^{85}\text{Kr}$  in the air, even during a period of active atmospheric weapons testing, is due to reprocessing of reactor fuel. This conclusion is strongly supported by evaluation of the data of Logsdon and Chissler (27) and Kahn *et al.* (28) which shows that about 0.02% of the  $^{85}\text{Kr}$  formed in reactor operations from 1959 through 1968 was released to the air at the reactor.<sup>3</sup> The  $^{85}\text{Kr}$  produced in reactor fuels is not released, in the absence of cladding failure or "tramp" uranium,<sup>4</sup> until the fuel elements are cut apart in the reprocessing plant and the fuel is dissolved preparatory to chemical separations. Goode (29) reported that 99-99.5% of the release occurs in the dissolution phase with acid treatment of  $\text{ThO}_2\text{-UO}_2$  fuel in the laboratory. This estimate is confirmed for full scale processing by data of Cochran *et al.* (30) who report that all but about 20-50 curies of the approximately 5,000 curies of  $^{85}\text{Kr}$  released per batch processed at the Nuclear Fuel Services plant are released during dissolution. Other radioactive gases released during reprocessing include  $^{131}\text{I}$ ,  $^{129}\text{I}$ ,  $^{131}\text{mXe}$ ,  $^{133}\text{Xe}$  and  $^3\text{H}$ . Krypton 85 is the only gas, other than  $^3\text{H}$ , released in sufficient quantity and having a half life long enough to produce significant widespread concentrations in the air. Whipple (50) estimates that  $^{85}\text{Kr}$  emission will limit U.S. nuclear power to about 150,000 MW(e).<sup>5</sup>

---

<sup>3</sup>Assuming 0.2 kCi of  $^{85}\text{Kr}$  produced/MW-year, all beta-gamma activity released to air by PWR/HTGR was  $^{85}\text{Kr}$  and 0.001% of total fission gas release from BWR was  $^{85}\text{Kr}$  (Estimated from isotope composition data in 27,28).

<sup>4</sup>According to Kahn *et al.* (28), the principal sources of fission products in reactor coolant are holes or cracks in cladding or fission of uranium in the coolant that has escaped from failed fuel elements. Tramp uranium and direct diffusion through intact cladding are minor sources.

<sup>5</sup>The release limit by the U.S. power industry was determined to be  $10^{10}\text{Ci/year}$  assuming (a)  $(\text{MPC})_a$  of  $3 \times 10^{-7} \mu\text{Ci/cm}^3$  reduced by 1/3 for individual variations and 1/10 for summing of dose from several isotopes, (b) half the  $^{85}\text{Kr}$  released is from explosion (U.S.), (c) all  $^{85}\text{Kr}$  produced is released, and (d) the U.S. uses 0.06 of world capacity (fair share based on population).

Small amounts of  $^{85}\text{Kr}$  have been released by venting of cavity gas from certain Plowshare projects such as Gasbuggy and Rulison. Gasbuggy produced an estimated 350 Ci of  $^{85}\text{Kr}$  which resulted in a cavity gas concentration of  $2.8 \mu\text{Ci}/\text{ft}^3$  (31,32). The  $^{85}\text{Kr}$  concentration in the cavity decreased exponentially as gas was removed (32-35). The amount of  $^{85}\text{Kr}$  released by these tests is minor in comparison to total  $^{85}\text{Kr}$  releases, but is of the same magnitude as the amount of  $^{85}\text{Kr}$  released at reactor sites through 1968.




Figure 2. Estimated krypton-85 concentrations in air, 1970-2060.

DISTRIBUTION OF  $^{85}\text{Kr}$ WORLDWIDE CONCENTRATION AND DOSE ESTIMATES

Coleman and Liberace (13) estimated future world  $^{85}\text{Kr}$  levels, and radiation doses resulting therefrom, based on projected world energy requirements and that part expected to be met with nuclear power. Their estimates, shown in figures 2 and 3, assume that all  $^{85}\text{Kr}$  produced is released and that the (MPC)<sub>a</sub> actually delivers the permitted dose. Their estimates of air concentrations, published data from a number of laboratories (25,26,36-45), and estimates of the United Kingdom contribution




Figure 3. Estimated annual dose from krypton-85, 1970-2060.

(24) were converted to a common unit and are shown in figure 4.<sup>6</sup> Data from Shuping *et al.* (44,45) are shown in figure 5 with the time scale expanded. The  $^{85}\text{Kr}$  levels appear to be increasing at a rate near or slightly greater than the predictions. The predictions were not claimed to be accurate in the 1965-1980 period mainly because of uncertainty in the time delays from irradiation to reprocessing.




Figure 4. Comparison of estimated  $^{85}\text{Kr}$  concentration in air, 1970-2060 with measurements through 1970.

<sup>6</sup>In converting the U.K. data, the cumulative  $^{85}\text{Kr}$  was assumed to be diluted into the total atmosphere of  $5.14 \times 10^{21}$  g at  $0.001293$  g/cm<sup>3</sup> ( $3.97 \times 10^{18}$  m<sup>3</sup>) which yields a conversion factor of  $\text{MCi}/3.97 = \text{pCi}/\text{m}^3$ .






Figure 5. Krypton-85 concentration in air, including data from Ehhalt *et al.* (25).

The data from figure 3 have been replotted in figure 6 for comparison with similar estimates from Dunster and Warner (24), Cowser *et al.* (46,47) and Csongor (38). The U.K. estimates (24) are based on *de novo* dose calculations while the others assume that a dose of 0.5 rem is delivered when the average concentration is  $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$  for one year. The calculations involved are discussed in the section on hazard evaluation.

Krypton 85 in commercial krypton supplies began causing problems as early as 1963 when Ostroski and Jelen (43) reported background problems with krypton-filled ionization chambers. Lasseart and Kellershohn (48) reported similar problems with self-triggering spark chambers in 1965. Dunster and Warner (24) warn of the possibility of personnel hazards associated with handling commercial krypton supplies long before atmospheric concentrations present a significant problem.

For comparison, the cumulative whole-body radiation dose from all nuclear testing conducted through 1962 (end of large scale atmospheric tests) is estimated to be 110 mrem in 30 years (49), which is itself about 1/30 of the dose received from natural sources over the same period (peak dose rates from fallout are greater).




Figure 6. Estimations of annual dose rates from  $^{85}\text{Kr}$ .

#### $^{85}\text{Kr}$ CONCENTRATIONS AND DOSES NEAR REPROCESSING FACILITIES


Personnel of the Northeastern Radiological Health Laboratory of the Bureau of Radiological Health, PHS, DHEW, have investigated the  $^{85}\text{Kr}$  concentrations in the vicinity of the Nuclear Fuel Services reprocessing plant at West Valley, New York, which is the only operating commercial fuel processing facility. These data are reported in references (30) and (51). Concentrations were monitored, as near to the periphery of the NFS property as access roads permitted, during the dissolution of several batches of fuel (about 1 ton/batch). Using data collected in

ENVIRONMENTAL PROTECTION AGENCY  
Office of Research and Monitoring  
12720 Twinbrook Parkway  
Rockville, Maryland 20853  
March 1, 1972

ERRATA SHEET:

Please make the following corrections on page 11,  
lines 5 and 6 of the report: "Krypton 85, A Review of the  
Literature and an Analysis of Radiation Hazards."

".... annual doses of 0.05 rem and 0.03 rem  
respectively, ..." should read "....annual  
doses of 0.05 mrem and 0.3 mrem respectively..."

A handwritten signature in cursive script that reads "Donald M. Hodge".

Donald M. Hodge  
Chief, Technical Reports Office

1968 and early 1969, Shleien (51) reported that the average annual  $^{85}\text{Kr}$  concentration at the plant boundary (1.5 km from the stack) would be  $2.3 \times 10^{-11} \mu\text{Ci}/\text{cm}^3$  and that the maximum annual concentration would be  $1.3 \times 10^{-10} \mu\text{Ci}/\text{cm}^3$ . These values, derived from plume measurements using wind data and diffusion equations, correspond to annual doses of 0.05 rem and 0.03 rem respectively, if the ICRP values are used to convert the concentrations to doses. In a later report, Cochran *et al.* (30) reported that the  $^{85}\text{Kr}$  concentrations in the plume ranged from  $1.7 \times 10^{-8}$  to  $7.65 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$  average for a 3-hour dissolution cycle; the peak values during the same time were  $1.3 \times 10^{-7}$  to  $9.3 \times 10^{-6} \mu\text{Ci}/\text{cm}^3$ . They calculated that the highest annual concentration,  $1.7 \times 10^{-10} \mu\text{Ci}/\text{cm}^3$ , would occur at the property line in the north octant. The maximum 24-hour off-property concentration was estimated to be  $6.8 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$ . Sax *et al.* (36) reported a concentration of  $5.6 \times 10^{-10} \mu\text{Ci}/\text{cm}^3$  about 5 miles from the plant on one occasion in February 1968.

Dunster and Warner (24) estimate that the dose to individuals in the vicinity of United Kingdom reprocessing facilities in 2000 AD will be about 45 mrad/year to the skin and 0.38 mrad/year to the gonads.

#### REMOVAL OF $^{85}\text{Kr}$ FROM PROCESS STREAMS BEFORE RELEASE TO THE ATMOSPHERE

It seems improbable that overall atmospheric  $^{85}\text{Kr}$  concentrations will require corrective or preventive action on purely radiological safety grounds before sometime in the next century (13,24). However, the anticipated growth in size of reprocessing facilities, coupled with increasing cost of enough land to permit MPC to be reached by diffusion before the plume crosses the property line, will probably lead to installation of equipment to remove the  $^{85}\text{Kr}$  from the process stream before it leaves the stack. Blomeke and Perona (52) and Perona *et al.* (53) estimate that this point will be reached when more than 5 tons/day of 150-day aged fuel or 0.5 ton/day of 30-day fuel is reprocessed.<sup>7</sup> East Germany requires facilities for storing  $^{85}\text{Kr}$  originating in reprocessing plants (54).

Concern with removal of  $^{85}\text{Kr}$  dates to the late 1950's (13,55-57). A number of techniques have been investigated including:

1. Adsorption onto activated charcoal at cryogenic temperatures (24,58-61 and many others)
2. Solvent extraction (24,42,55,56,62-64)
3. Condensation in liquid nitrogen followed by fractional distillation (65)
4. Selective permeating through cellulose acetate or silicone rubber membranes (66,67).

---

<sup>7</sup>Their analysis included contribution from all noble fission gases, but only  $^{85}\text{Kr}$  is important 150 days after cooling.

Three of these techniques have been developed to the operating stage. The solvent extraction method developed at the Oak Ridge Gaseous Diffusion Plant over the past several years (63,64) was recently reported to be commercially available (62). A plant using the  $\text{LN}_2$  condensation-redistillation technique is in use at the Idaho Chemical Processing Plant (NRTS) (65). Air and Water News (62) also reports that one commercial reactor supplier is using a charcoal bed removal system.

The most practical disposition for recovered  $^{85}\text{Kr}$  appears to be long-term storage in high pressure steel cylinders (24,52,53). Incorporation of  $^{85}\text{Kr}$  into glasses, resins, clathrates, molecular sieves, and pressurized steel or glass bulbs in an epoxy matrix have been considered for secondary containment of the  $^{85}\text{Kr}$  inside the steel cylinders (68). Serious attention has been given to the possibility of pumping  $^{85}\text{Kr}$  into underground storage areas, such as abandoned gas or oil wells or similar formations (52,69,70). This method requires a porous storage formation with an essentially non-porous cap formation that is free of vertical channels. This requirement is too restrictive to permit generalized use at reprocessing plant sites.

One comprehensive proposal, made by Blomeke and Perona (52,53), calls for separating the  $^{85}\text{Kr}$  from the process stream, alone or with xenon, by solvent extraction or cryogenic distillation. Processing 2600 tons/year of LWR<sup>8</sup> fuel is estimated to yield 28 cylinders, each containing 50 liters or  $10^6$  Ci of  $^{85}\text{Kr}$  (heat production 5,800 BTU/hour), or 160 cylinders each containing 50 liters of mixed Kr/Xe (180,000 Ci  $^{85}\text{Kr}$ , heat production 1000 BTU/hour). The cylinders would be temporarily stored underwater on site and then shipped, in special water-cooled casks, to underground salt mines and stored above the floor in sealed rooms. The storage space requirement for one year's production is one quarter acre and is determined by heat production. The cost of disposal of  $^{85}\text{Kr}$  by this technique, including (1) filling, testing, and on-site storage of the cylinders, (2) shipment to a salt mine, and (3) permanent storage in the salt mine, is estimated to be \$190,000-220,000/year for a 2600 ton-year plant. This amounts to 0.0003-0.00035 mills/kW-hr of electricity generated by the reprocessed fuel. This is about 0.001% of the residential electric rate in Rochester, New York in 1971.

Dunster and Warner (24) make basically similar proposals except that they consider solvent extraction or adsorption on activated charcoal to concentrate the  $^{85}\text{Kr}$  and evaluated several different types of storage tanks.

---

<sup>8</sup>The fuel considered is from a light water reactor (LWR) exposed to 33,000 MWd/ton at 30 MW/ton. An equivalent amount of fuel from a liquid metal fast breeder reactor (mixed core and blanket) with an average exposure of 33,000 MWd/ton at 58 MW/ton will yield about 10% less volume of noble gases.

## USES OF KRYPTON 85

### MEDICINE AND CLOSELY ALLIED AREAS

Krypton 85 has found important clinical use in the past 15 years. Its physiological characteristics of low blood solubility, high lipid solubility, and rapid diffusion, together with versatility of detection, facilitate differential diagnosis. Specific applications have included:

1. Determination of total body fat (71-75)
2. Circulatory studies
  - a. General (72, 76-86)
  - b. Rate of blood flow
    - (1) Brain
      - (a) Whole and regional (87-116)
      - (b) Partition coefficients (100, 117, 118)
      - (c) Detection of lesions (87, 102, 119)
    - (2) Heart
      - (a) Output (120-125)
      - (b) Myocardial flow (126-132)
    - (3) Lungs and perfusion (133-140)
    - (4) Kidneys (108, 141-146)
    - (5) Skin (147-149)
    - (6) Gastric mucosa (150-152)
    - (7) Intestines (153-155)
    - (8) Liver (156, 157)
    - (9) Eyes (158, 159)
    - (10) Muscle (106, 160)
    - (11) Testis (161)
    - (12) Tumors (162)
    - (13) Fresh grafts (163)
  - c. Circulatory shunts
    - (1) Left-to-right, including atrial septal defects, ventricle septal defects, and patent ductus (164-173)
    - (2) Right to left (pulmonary) (168, 174-179)
    - (3) Hepatic-pulmonary (177)
    - (4) Hepatic to vena cava (180)
    - (5) A-V aneurisms in brain (117)
3. Lung function studies - emphysema, cysts, cancer etc. (133-140, 181-183)
4. Structure of teeth (crystalline) (184)
5. Determination of surface area of elastin (185)

The quantities of  $^{85}\text{Kr}$  used in these studies have usually been in the  $\mu\text{Ci}$ - $\text{mCi}$  range.

## NON-MEDICAL USES OF $^{85}\text{Kr}$

The non-medical uses of  $^{85}\text{Kr}$  can be divided into two areas: (1) those that use  $^{85}\text{Kr}$  as the gas and (2) those that incorporate it into solids prior to use. Examples of the first category are:

1. Replacement of radium bromide as an ionization source in cold cathode gas discharge tubes (186)
2. Location of carbon monoxide leak into aircraft cabins in flight (187)
3. Measurement of stream aeration (188)
4. Determination of surface area of atmospheric particulates (189)
5. Measurement of gas flow in piping systems (190)
6. Tests of gaseous diffusion theory in solids (68, 69, 191)
7. Measurement of stack gas dispersion and diffusion (31, 192-197)
8. Study of interhemispheric atmospheric mixing (39)
9. Study of other atmospheric gases (40, 41)

Krypton 85 has been incorporated into or onto solids using techniques recently reviewed by Balek (5) and by Eddy (198). Methods include: (1) fission recoil, (2) bombardment of surfaces with high-energy  $^{85}\text{Kr}$  ions, (3) diffusion into crystal lattices at high temperatures and pressures (successful with over 150 materials), (4) crystallization of solids from melt or by sublimation in an  $^{85}\text{Kr}$  atmosphere and (5) by adsorption onto outgassed surfaces. All but the last method yield more or less stable products which are called kryptonates if surface labeled, as by the first three methods, or clathrates if the  $^{85}\text{Kr}$  is incorporated throughout the material as by the fourth method.

The distribution of  $^{85}\text{Kr}$  can be determined by autoradiography, or its electronic equivalent, and used to study structural features of solid materials including surface phenomena, lattice structure, or channeling (5, 199-201). Cracks and imperfections in machinery components, such as turbine blades, can be detected after either kryptonation or adsorptive labeling. Autoradiography is the only technique sensitive enough to use with the kryptonated materials while either autoradiography or electronic imaging works well with the adsorptive technique.

Another potentially extensive use of kryptonates and krypton clathrates lies in the field of chemistry (4, 5, 202). Krypton 85 can be incorporated into one of the reactants, catalysts, or incidental materials, and the release of the gas from the solid used to detect the beginning of a reaction or to measure its rate. Reaction end points, such as in titrations, can be objectively determined by including in the solution a kryptonated solid that will not react until an excess of titrant is present.

The amount of  $^{85}\text{Kr}$  involved in non-medical uses is rarely mentioned; however, some of the counting data presented and description of the procedures suggest that some procedures may use curie quantities.

## RADIATION HAZARDS ASSOCIATED WITH $^{85}\text{Kr}$

### SKIN DOSE

The dose to the skin from a cloud of  $^{85}\text{Kr}$  is the sum of doses from beta particles, gamma rays and Bremsstrahlung from the surrounding atmosphere and from the  $^{85}\text{Kr}$  that has been absorbed into the body. In the circumstances postulated in deriving the  $(\text{MPC})_a$ , only the contribution from outside the body is significant; the internal contribution will be 1-2 orders of magnitude less than the external gamma/Bremsstrahlung component and 4-5 orders of magnitude less than the dose delivered to the skin by external beta radiation.

The surface beta dose in an infinite cloud of a beta-emitting gas such as  $^{85}\text{Kr}$  is given by:

$$D = 1.07 \times 10^{-6} C_a \bar{E} K \text{ rad/hour} \quad (24)$$

where:  $C_a$  = pCi  $^{85}\text{Kr}$ /gram of air  
 $\bar{E}$  = average beta energy in MeV = 0.249 MeV<sup>9</sup> (11)  
 $K$  = ratio of stopping power in tissue to stopping power in air = 1.15 (24)

This reduces to:

$$D = 3.064 \times 10^{-7} C_a \text{ rad/hour} = 2.68 \times 10^{-3} C_a \text{ rad/year}$$

or

$$D = 2.07 C'_a \text{ rad/year where } C'_a = \text{pCi } ^{85}\text{Kr}/\text{cm}^3 \text{ air}^{10}$$

This equation represents 50% of the point dose at the center of an infinite cloud of  $^{85}\text{Kr}$  or the dose at the surface of an infinite slab of  $^{85}\text{Kr}$ , multiplied in either case by the stopping power ratio.

The expression for the dose to the surface of the body from gamma radiation and Bremsstrahlung was derived by N. Adams in Appendix 1 to reference (24). This dose is given by the expression:

$$D = 2.42 \times 10^{-9} C_a \text{ rad/hour} = 2.12 \times 10^{-5} C_a \text{ rad/year}$$

or

$$D = 1.64 \times 10^{-2} C'_a \text{ rad/year}$$

where  $C_a$  = pCi  $^{85}\text{Kr}$ /gram of air and  $C'_a$  = pCi  $^{85}\text{Kr}/\text{cm}^3$  of air as above.

---

<sup>9</sup>Reference (24) uses 0.234 MeV. Results differ accordingly.

<sup>10</sup>Using 1 cm<sup>3</sup> air = 0.001293 gram air.



## DOSE IN THE BODY

DOSE FROM  $^{85}\text{Kr}$  OUTSIDE THE BODY

The average dose to the total body from gamma radiation and Bremsstrahlung from  $^{85}\text{Kr}$  outside the body (infinite cloud) is given by (24-Appendix 1):

$$D = 1.97 \times 10^{-9} C_a \text{ rad/hour} = 1.73 \times 10^{-5} C_a \text{ rad/year}$$

or

$$D = 1.38 \times 10^{-2} C_a' \text{ rad/year}$$

DOSE FROM  $^{85}\text{Kr}$  CONTAINED IN THE BODY

To calculate the dose of  $^{85}\text{Kr}$  in the body that results from a given concentration of the isotope in the surrounding air, the fraction of the air concentration that will ultimately be found in the body, or a specific part thereof, must be known. This fraction is the partition coefficient which is usually designated as  $\lambda$ .

The internal behavior of  $^{85}\text{Kr}$  is discussed in detail in Appendix A, including gas solubility, partition coefficients, and kinetic parameters. The partition coefficient for the body or a particular tissue is largely dependent on its fat content and for  $^{85}\text{Kr}$  is closely approximated by:

$$\lambda \text{ tissue:air} = 0.06 \frac{(9V_f + V_r)}{V_t} = (0.48V_f/V_t) + .06$$

where:  $V_t$  = total tissue volume,  $V_t = V_f + V_r$   
 $V_f$  = volume of fat in tissue  
 $V_r$  = volume of rest of tissue

Thus the partition coefficients from body tissue to air ranges from 0.06 to 0.54. The average partition coefficient for standard man is 0.163

To calculate the tissue concentration of  $^{85}\text{Kr}$  at equilibrium, the air concentration is multiplied by the partition coefficient. If tissue density is unity, the result is in pCi/gram.

The dose which results from the gamma and Bremsstrahlung component of  $^{85}\text{Kr}$  in the body is given by (24, Appendix 1):

$$D = 1.43 \times 10^{-9} C_t \text{ rad/hour} = 1.25 \times 10^{-5} C_t \text{ rad/year}$$

where  $C_t$  = pCi  $^{85}\text{Kr}$ /gram of tissue ( $C_t = C_a' \times \lambda$ )

The beta component of internal dose is given by:

$$\begin{aligned}
 D &= C_t \text{pCi/g} \times 2.22 \text{ disintegrations/pCi-min} \times 0.9959 \text{ beta/dis-} \\
 &\quad \text{integration} \times 0.249 \text{ MeV/beta} \times 1.6021 \times 10^{-6} \text{ ergs/MeV} \times \\
 &\quad \text{rad-g/100 ergs} \times 60 \text{ min/hour} \\
 &= 5.29 \times 10^{-7} C_t \text{rad/hour} = 4.62 \times 10^{-3} C_t \text{rad/year}
 \end{aligned}$$

$$\begin{aligned}
 \text{If } \lambda \text{ air:tissue} &= 0.06; D = 2.77 \times 10^{-4} C'_a \text{ rad/year} \\
 \lambda \text{ air:tissue} &= 0.163; D = 7.58 \times 10^{-4} C'_a \text{ rad/year} \\
 \lambda \text{ air:tissue} &= 0.54; D = 2.50 \times 10^{-3} C'_a \text{ rad/year}
 \end{aligned}$$

where  $C'_a = \text{pCi } ^{85}\text{Kr/cm}^3$  in the surrounding air.

#### DOSES TO SKIN, WHOLE BODY AND MALE GONADS AT UNRESTRICTED (MPC)<sub>a</sub>

An individual continuously submerged in an infinite cloud of  $^{85}\text{Kr}$  at a concentration of  $3 \times 10^{-7} \text{ } \mu\text{Ci/cm}^3$  ( $C'_a = 0.3 \text{ pCi/cm}^3$ , with an air density of  $0.001293 \text{ g/cm}^3$   $C_a = 232.56 \text{ pCi/g air}$ ) receives the following annual doses.

##### SKIN (SURFACE)

$$\begin{aligned}
 \text{External beta dose} &= 2.073 C'_a \text{ rad/year} = & 0.623 \text{ rad} \\
 \text{Gamma and Bremsstrahlung dose} &= 1.64 \times 10^{-2} C'_a \text{ rad/year} = & 0.00493 \text{ rad} \\
 \text{Total} &= & \underline{0.628 \text{ rad}}
 \end{aligned}$$

##### GONADS (MALE)

$$\begin{aligned}
 \text{Gamma and Bremsstrahlung dose at surface} &= \\
 1.64 \times 10^{-2} C'_a \text{ rad/year} &= 4.93 \times 10^{-3} \text{ rad}
 \end{aligned}$$

$$\begin{aligned}
 \text{Gamma and Bremsstrahlung dose from } ^{85}\text{Kr} \text{ inside the body } (\lambda = .06) &= \\
 1.25 \times 10^{-5} C_t \text{ rad/year} &= 7.5 \times 10^{-7} C'_a \text{ rad/year} = 2.25 \times 10^{-7} \text{ rad}
 \end{aligned}$$

$$\begin{aligned}
 \text{Internal beta dose } (\lambda = .06) &= \\
 2.77 \times 10^{-4} C'_a \text{ rad/year} &= & 8.33 \times 10^{-5} \text{ rad} \\
 \text{Total} &= & \underline{5.01 \times 10^{-5} \text{ rad}}
 \end{aligned}$$

##### WHOLE BODY ( $\lambda = 0.163$ )

$$\begin{aligned}
 \text{Gamma and Bremsstrahlung dose from } ^{85}\text{Kr} \text{ outside the body} &= \\
 = 1.38 \times 10^{-2} C'_a \text{ rad/year} &= 4.02 \times 10^{-3} \text{ rad}
 \end{aligned}$$

Gamma and Bremsstrahlung dose from  $^{85}\text{Kr}$  inside the body =

$$1.25 \times 10^{-5} C_t \text{ rad/year} =$$

$$2.04 \times 10^{-6} C_a \text{ rad/year} = 6.12 \times 10^{-7} \text{ rad}$$

Internal beta dose =

$$4.62 \times 10^{-3} C_t \text{ rad/year} =$$

$$7.58 \times 10^{-4} C_a \text{ rad/year} = \frac{2.27 \times 10^{-4} \text{ rad}}{}$$

$$\text{Total} \quad 4.25 \times 10^{-3} \text{ rad}$$

#### OTHER DOSE CALCULATIONS

Depth-dose calculations presented by Hendrickson (203, 204) illustrate the discrepancies between the surface dose and the actual dose in several critical tissues (ignoring contributions from  $^{85}\text{Kr}$  in the body). The results of these calculations, which include contributions from beta, gamma, and Bremsstrahlung, for an  $^{85}\text{Kr}$  concentration of  $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$  are given in table 1.

TABLE 1.<sup>a</sup> ANNUAL DOSE FROM IMMERSION IN AIR  
WITH A CONCENTRATION OF  $3 \times 10^{-7} \mu\text{Ci}(^{85}\text{Kr})/\text{Cm}^3$

Tissue	Tissue Depth (mm)	$\beta$ Radiation (rem/yr)	$\alpha$ and $\gamma$ Radiation (rem/yr)
Whole Body	50	Nil	0.007
Gonads	10	Nil	0.007
Gonads	2	$4 \times 10^{-7}$	0.007
Surface of Skin (or clothing)	0.0	0.5	0.007
Skin (shallowest layer of live skin)	0.07	0.3	0.007
Lens of Eye	2	$4 \times 10^{-7}$	0.007
Lung	(Internal Sur- face of Lung)	0.005 <sup>b</sup>	0.007

<sup>a</sup>From Hendrickson (203).

<sup>b</sup>Internal exposure to surface lung tissue from  $^{85}\text{Kr}$  in the lung.

Detailed calculations of doses resulting from immersion in infinite clouds of the various reactor-produced noble gases, including  $^{85}\text{Kr}$ , using the MIRD<sup>11</sup> methodology are nearing completion and will be published in the near future (205).

Relationships for calculating doses to various organs resulting from inhalation or injection of  $^{85}\text{Kr}$  during the medical diagnostic procedures previously mentioned have been derived by Lassen (206) who estimates that the following doses would result from breathing  $^{85}\text{Kr}$  at a concentration of  $1\ \mu\text{Ci}/\text{cm}^3$  for 1 minute:

Tracheal mucosa	71.9 mrad
Lungs	27.3 mrad
Adipose tissue	4.2 mrad
Other (incl. gonads)	0.5 mrad

These values would change relative to each other as exposure time increases. The original paper should be consulted for details.

#### COMPARISON OF DOSES DELIVERED AT $(\text{MPC})_a$ WITH PERMITTED DOSES

ICRP 9 (207) summarizes dose limits for occupational exposure and exposure to members of the public as shown in table 2. An additional limit is the recommended whole population genetic limit of 5 rems/30 years (0.167 rem/year).

TABLE 2<sup>a</sup>. SUMMARY OF DOSE LIMITS FOR INDIVIDUALS

Organ or Tissue	Maximum Permissible Doses for Adults Exposed in the Course of Their Work (rems in a year)	Dose Limits for Members of the Public (rems in a year)
Gonads, red bone marrow, whole body	5	0.5
Skin, bone, thyroid	30	3
Hands and forearms, feet and ankles	75	7.5
Other single organs	15	1.5

<sup>a</sup>From ICRP-9 (208).

<sup>11</sup>Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine.

Figure 7 shows the fractions of applicable limits delivered by  $^{85}\text{Kr}$  at a concentration of  $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^3$ , to the skin, gonads, and whole body. The full bar in each case represents the fraction given in an infinite cloud with exposure time long with respect to body saturation time. The shaded area of the bar represents the fraction delivered without the external gamma/Bremsstrahlung component. The numbers in parentheses are the factor by which the  $(\text{MPC})_a$  is conservative for each case. It appears that the  $(\text{MPC})_a$  is conservative by a factor of at least 4.8 and, when shielding effects of clothing and buildings are considered, probably by a much larger factor. Modifying factors of particular importance in the occupational situation are heavy clothing, such as lab coats, and the absence of an infinite cloud with respect to gamma radiation. For example, if  $50 \text{ mg}/\text{cm}^2$  of clothing is worn reasonably close to the body, the skin




Figure 7. Comparison of estimations of annual dose rates from  $^{85}\text{Kr}$ .

beta dose would be 18% of the unclothed dose so the total skin dose/year at  $3 \times 10^{-7} \mu\text{Ci}/\text{cm}^2$  would be 0.112 rad beta + 0.005 rad gamma or 0.117 rad/year.<sup>12</sup> This is conservative by a factor of 25.6. The controlling dose would then be the extremity dose which is conservative by a factor of  $7.5/0.628 = 12$ .

An increase in the unrestricted  $(\text{MPC})_a$  by a factor of 5 and the occupational  $(\text{MPC})_a$  by a factor of 10-12 would appear justifiable if the only consideration is meeting existing dose limits, but may not be desirable when other things are considered.

### UNEXPLAINED PHENOMENA INVOLVING "INERT" GASES

A number of inert gas phenomena, reported in the literature, have not been satisfactorily explained. These have all occurred at pressures many times greater than those considered in radiation protection, but may be applicable to the physiological behavior of  $^{85}\text{Kr}$  and must be considered. The relative magnitude of effects found with members of the helium series usually have been in order of polarizability or oil solubility which is  $\text{Xe} > \text{Kr} > \text{A} > \text{Ne} > \text{He}$ .

The growth of *Neurospora crassa* was inhibited by 50% with 0.8 atm. of Xe, 1.6 atm. of Kr, 3.8 atm. of A, 35 atm. of Ne and 300 atm. of He (208); the inhibition of growth at 650 mm pressure was found to be proportional to the square root of the atomic weight of the gas.

High pressures of xenon (225 psi) led to cessation of motion, a decrease in contractile vacuole activity, increase in cell volume and surface area and cytotoxicity in paramecia (209). Krypton produced a decrease in contractile vacuole activity at 915 psi.

Reversible inhibition of  $\text{Na}^+$  transport across frog skin was found at 200 psi xenon or 950-1000 psi krypton (210). Similar pressures caused reversible blockage of frog sciatic nerve transmission. In similar frog nerve-muscle preparations, 100 psi xenon caused a decrease in muscle contraction and nerve conduction and 200 psi krypton decreased muscle contraction (211).

Radioprotection by inert gases is reported for animals (212) and bean sprouts (8) although krypton had no protective effect on mice at 2 atmospheres pressure (213). Markoe *et al.* (214) reported potentiation of killing of HeLa cells by x rays which was proportional to the partial pressure of Xe or Kr present at irradiation.

---

<sup>12</sup>Since the limits for members of the public are each 1/10 of the corresponding occupational limit, the degree of conservativeness calculated for one applies to the other.

Possibly the most interesting mystery is the demonstrated anesthetic action of xenon (6) in humans. Surgical procedures (orchidectomy and Fallopian tube ligation) have been performed using an 80% Xe:20% O<sub>2</sub> mixture (1 atm. total pressure) for anesthesia. Higher partial pressures of Xe are required to anesthetise animals. The narcotic potency of the helium series seems to follow the order previously stated (215) although narcotic effects of krypton are equivocal at atmospheric pressures (6).

Another observation that has not been accounted for is the uptake of 1 1/2 2 times as much inert gas by the adrenal as by any other tissues (8).

The foregoing phenomena are not understood at this time although they have been widely debated (3, 7, 8). The most popular postulates, particularly for anesthesia, are membrane effects involving lipid solubility or stabilization of the formation of hydrate microcrystals in the nervous system to block electrical conduction.

## SAMPLING AND ANALYSIS OF <sup>85</sup>KR

### DETECTION AND COUNTING

#### GENERAL

Krypton 85 has been successfully detected and counted by virtually every conventional beta or gamma detection technique, and some unconventional ones, when sampling methods and counting techniques have been properly matched with the amount and concentration of isotope to be analyzed and its physical form or configuration.

#### DETECTORS USED

*GM Counters:* GM counting has been used extensively in the medical studies cited. End window GM detectors were used to count the beta radiation emitted from the surface of organs, thin-windowed sample containers, or flowing gas mixtures. Internal GM counters have been used to analyze environmental samples (43).

The detection efficiency of end-window GM tubes is determined by many factors and may approach 50% with good geometry and thin windows. Martin (192) showed that commercial GM tubes with 30 mg/cm<sup>2</sup> walls will detect  $5 \times 10^{-7}$   $\mu$ Ci/cm<sup>3</sup> of <sup>85</sup>Kr in an infinite cloud geometry. Ludwick *et al.* (194), using a very sensitive tube with a 3.5 mg/cm<sup>2</sup> window 50 mm in diameter, were able to detect the passage of a cloud with a concentration of  $10^{-7}$   $\mu$ Ci/cm<sup>3</sup>. GM tubes coupled to ordinary survey meters have been successfully used to assay the concentration of <sup>85</sup>Kr in

pressurized steel cylinders (216). Most recently, Smith *et al.* (217) report calibration of several types of GM detectors to  $^{85}\text{Kr}$  in a known fraction of an infinite cloud. Their results are shown in table 3.

GM tubes are commonly used as stack monitors by placing them in a tank large enough to provide an appreciable fraction of an infinite cloud (for beta) and drawing part of the stack flow through the tank (30, 217).

*Internal Ionization Counters and Proportional Counters:* The standard technique of counting radioactive gases in internal proportional counters or ionization chambers has been used by several authors to analyze  $^{85}\text{Kr}$  in environmental samples (25, 31, 217-219) and is the method used in standardization. Gas flow proportional counting was used in conjunction with gas-phase chromatography by Dupuis *et al.* (220). Calibration data reported by Smith *et al.* (217) for various sized ionization chambers is shown in table 4. These same chambers were equipped with needle valves and flowmeters and used to obtain and count integrated atmospheric samples near the Nuclear Fuel Services plant by Cochran *et al.* (30). Cold trapping of xenon and radon was required.

Ionization chambers may be used in the flow-through mode as well as a static mode. This method was used in characterizing the  $^{85}\text{Kr}$  concentration used in calibrating GM tubes to infinite cloud geometry (217).

*Scintillation Counters: Gamma Scintillation* Next to GM counting, gamma scintillation counting using NaI(Tl) crystals is used most to assay  $^{85}\text{Kr}$ . The 0.514 MeV gamma photon emitted in about 0.43% of the  $^{85}\text{Kr}$  disintegrations penetrates tissue or sample containers easily and can be detected with the NaI(Tl) crystal. This has been the technique used in most of the papers reporting whole-body or whole-organ saturation or desaturation data and in laboratory analyses if the activity was high enough. The technique avoids the sample self absorption problems encountered with GM counting and the preparation problems involved with most of the following techniques. However, the low detection efficiency of the NaI combined with the low gamma emission rate of the  $^{85}\text{Kr}$  results in very low efficiency.

*Beta Scintillation* Both liquid and solid beta scintillation techniques have been used with  $^{85}\text{Kr}$ . Liquid scintillation has become an increasingly popular method of counting  $^{85}\text{Kr}$  and takes advantage of the high solubility of Kr in toluene based scintillation cocktails (44, 45, 221, 222). Very low specific activity samples may require concentration by cryogenic techniques before counting. According to Shuping *et al.* (44, 45), the lowest concentration that can be analyzed without preconcentration is about 3 pCi/ml. Counting efficiency is 92-100% and 0.014 pCi of  $^{85}\text{Kr}$  can be counted with good precision. The limiting problem with air mixtures is the poor solubility of the air in the scintillator. The undissolved air forms a pocket and part of the Kr goes out of solution into the air.



TABLE 3. MINIMUM DETECTABLE  $^{85}\text{Kr}$  CONCENTRATIONS FOR CALIBRATED  
EXTERNAL  $\beta$  DETECTORS [after Smith *et al.* (217)]

Count Time Background/Sample  Detector Type (Model)	Laboratory MDC (pCi/cm <sup>3</sup> )		Field MDC (pCi/cm <sup>3</sup> )	
	Long Count <sup>a</sup> 0.5/4 hr	Short Count <sup>b</sup> 10/10 min	Long Count <sup>c</sup> 0.5/4 hr	Short Count <sup>d</sup> 10/10 min
2 window pancake GM (Eon 8008H)	.007	.012	.020	.012
1 window pancake GM (Amperex 18546)	.011	.024	.042	.027
(Eon 8001T)	.014	.025	.040	.025
Cylindrical Probe (LND 719)	.011	.024	.043	.024
(Eon 5108E)	.013	.024	.046	.028
$\beta$ Scintillator (Pilot B)	.016	.029	.045	.029

Notes on counting conditions:

- (1) All values assume the  $\text{MDC} = 2s/C_{85}$  where  $s$  = the standard deviation of the measurement (CPM) and  $C_{85}$  = the calibration factor for the detector (CPM/(pCi/cm<sup>3</sup>)).
- (2) Total instrument errors are assumed to be negligible in each case.
- (3) The magnitude of the relative background variations ( $2s_{vb}/B$ , where  $B$  = background CPM and  $s_{vb}$  = standard deviation due to background level fluctuations) assumptions for the four counting interval combinations used are denoted by the following:

Superscript	Relative background variations ( $2s_{vb}$ )
a	4.8%
b	9.8%
c	27.4%
d	11.8%

- (4)  $0.3 \text{ pCi/cm}^3 (\text{MPC})_a$  for individuals in the general population, 10CFR20 (19).

TABLE 4. MINIMUM DETECTABLE CONCENTRATIONS FOR  $^{85}\text{Kr}$   
IN IONIZATION CHAMBERS<sup>a,b</sup>

Chamber volume (liters)	MDC $^{85}\text{Kr}$ Chamber Unshielded (pCi/cm <sup>3</sup> )	MDC $^{85}\text{Kr}$ Chamber/2" Pb Shields (pCi/cm <sup>3</sup> )
0.5	$1.3 \times 10^{-1}$	$1.5 \times 10^{-1}$
1.0	$1.9 \times 10^{-1}$	$1.5 \times 10^{-1}$
2.8	$3.9 \times 10^{-2}$	$3.1 \times 10^{-2}$
4.3	$3.9 \times 10^{-2}$	$2.3 \times 10^{-2}$

<sup>a</sup>Cary-Tolbert design (Applied Physics Corp.).

<sup>b</sup>After Smith *et al.* (217).

An ingenious counting technique, reported by Sax *et al.* (223) for environmental samples, employs cryogenic preconcentration by 5 Å molecular sieves at liquid nitrogen temperatures and counting tubes full of plastic scintillator shavings. The shavings are outgassed under vacuum and the concentrated sample is drawn into the tube by vacuum. The tubes are reusable after outgassing.

Smith *et al.* (217) also tested Pilot B scintillator for uses similar to those of GM tubes and found that it was less sensitive than the GM detectors (see table 3).

A pressurized scintillation chamber is described by Voice (224).

*Semi-conductor Detectors:* Semiconductor detectors of both the lithium-drifted pi-n (108) and the silicon p-n (225) types have been used in inert catheters for *in vivo* monitoring of  $^{85}\text{Kr}$  concentrations in the heart and lungs.

*Integrating Dosimeters:* Thermoluminescent dosimeters and film badges have both been used for monitoring  $^{85}\text{Kr}$  (226). The major drawback with both is difficulty in characterizing the exposure as to radiation type and energy to properly assess dose.

### CALIBRATION AND STANDARDIZATION

Krypton 85 gamma or beta calibration standards are available from the National Bureau of Standards or other suppliers. Secondary  $^{85}\text{Kr}$  standards can be prepared by comparison. Gamma calibration has been done with  $^{85}\text{Sr}$  sources, an adequate procedure when only the 0.514 MeV photo-peak is used. The Bremsstrahlung spectrum from  $^{85}\text{Kr}$  overwhelms the Compton shelf at lower energies and precludes using  $^{85}\text{Sr}$  without a lower discriminator. Also  $^{198}\text{Au}$  has been used as a counting standard (227) but is not recommended. GM tubes were calibrated to measure  $^{85}\text{Kr}$  beta radiation by immersion in a  $^{204}\text{Tl}$  solution (228). Data comparing the response to  $^{85}\text{Kr}$  in air and calibration factors are given.

### SAMPLING AND SAMPLE PREPARATION

The gaseous nature and relative chemical inertness of  $^{85}\text{Kr}$  preclude using the normal concentration techniques of drawing air through a filter or an activated charcoal cartridge at ambient temperature. With sufficient specific activity, an appropriate sample container can be filled and counted by any of the mentioned techniques, or a flow-through sampling and counting technique can be used with ionization or proportional counters. For samples of very low specific activity such as those collected in the environment at large, or samples containing other radioactive inert gases, concentration and/or separation by cryogenic techniques are the usual procedures. Molecular sieves (223, 229), activated charcoal (227, 229, 230), silica gel, vermiculite and alumina (229) have been successfully used as collectors with liquid nitrogen cooling. Copper wool was used successfully in a  $\text{LN}_2$  cooled cold trap to collect Xe (231) and was suggested for collection of Kr. Gas chromatography is becoming popular for analysis of  $^{85}\text{Kr}$  in the presence of other noble fission gases (220, 232-234). Direct condensation in  $\text{LN}_2$  or LOX, followed by redistillation has been used successfully (26, 64).

In theory, any of the separation techniques discussed under removing  $^{85}\text{Kr}$  from the air can be used. The ones not mentioned in this section have practical drawbacks such as bulk or less than 100% recovery. All of the adsorbing media have a finite capacity. The quantity of media used and the operating temperature must be matched to the flow rate and the sample size required, and the system must be tested in its designed service before field use is attempted.

### SUMMARY

Krypton 85 is an environmental contaminant for which progress in development of monitoring and control methodology appears to have outstripped knowledge and understanding of its biologic effects. Monitoring methods presently available, while subject to improvement, are adequate for routine use and several reasonable techniques for removing  $^{85}\text{Kr}$  from effluent gas streams have been demonstrated on at least pilot plant scale. On the other hand, the value judgments regarding the necessity for and stringency of control of release have been and are being based on calculations and extrapolations rather than on experimental data obtained with living systems. Data on the effects of both acute and chronic exposure of several animal species to  $^{85}\text{Kr}$  are needed to confirm these extrapolations.

Until the behavior and effects of radioactive noble gases in living systems are better understood, the basis for release regulations will continue to be founded entirely on radiation dose calculations. These calculations should be subjected to the scrutiny of *in vivo* experimentation. In the interim, control of the major source of  $^{85}\text{Kr}$  release, fuel reprocessing plants, to the lowest practical emission level is desirable. It may be appropriate, especially if the  $(\text{MPC})_a$  for unrestricted areas is relaxed, to require these plants and any other major source that may develop to control their release to levels much lower than necessary to reach the  $(\text{MPC})_a$  at plant boundaries.

Relaxation of the occupational  $(\text{MPC})_a$ , albeit justifiable by calculations, is subject to the same reservations. It appears more desirable to grant exceptions or modifications in individual cases for variations in exposure conditions, such as wearing of heavy clothing or absence of an infinite cloud, than to change the standard at this time.

REFERENCES

1. Chernick, C.L. The chemistry of the noble gases. United States Atomic Energy Commission, Division of Technical Information, Library of Congress Catalog Card Number: 67-62972, (1967).
2. Streng, A.G. and A.V. Grosse. Acid of krypton and its barium salt. *Science* 143:242-243 (1964).
3. Featherstone, R.M. The molecular pharmacology of anesthesia. *Fed. Proc.* 27:870-871 (1968).
4. Lindquist, K.O. and W.S. Diethorn. Kinetics of rare gas release from hydroquinone clathrates. *Int. J. Appl. Radiat. Isot.* 19:333-344 (1968).
5. Balek, V. Radioactive inert gases tool for analysis. *Anal. Chem.* 42:16A-18; 20A; 22A-3; 25A-6; 28A; 30A-1 (August 1970).
6. Cullen, S.C. and E.G. Gross. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. *Science* 113:580-582 (1951).
7. Pauling, L. A molecular theory of general anesthesia. *Science* 134:15-21 (1961).
8. Featherstone, R.M. and C.A. Muehlbaeher. The current role of inert gases in the search for anesthesia mechanisms. *Pharmacol. Rev.* 15:97-121 (1962).
9. Nussbaum, E. Radon solubility in body tissues and in fatty acids. Ph.D. Thesis, University of Rochester, Dept. of Radiation Biology (1957).
10. *Cryogenic Reference Data*. Union Carbide Corp., Linde Division (1967).
11. *Radiological Health Handbook* (Rev.). Bureau of Radiological Health and the Training Institute, Environmental Control Administration, U.S. Dept. of Health, Education and Welfare, Public Health Service, Consumer Protection and Environmental Health Service, Rockville, Md. 20852 (January 1970).
12. National Bureau of Standards. Certificate (Provisional), Standard Reference Material 4235, Radioactivity Standards Krypton-85. Washington, D.C. 20234, (October 1969).
13. Coleman, J.R. and R. Liberace. Nuclear power production and estimated krypton-85 levels. *Radiol. Health Data Rep.* 7:615-621 (1966).
14. Katcoff, S. Fission-product yields from neutron-induced fusion. *Nucleonics* 18:203 (November 1960).

15. Katcoff, S. and W. Rubinson. Yields of  $^{85}\text{Kr}$  in thermal neutron fission of  $^{235}\text{U}$  and  $^{239}\text{Pu}$ . J. Inorg. Nucl. Chem. 27:1447-50 (July 1965).
16. Meek, M.E. and B.F. Rider. Summary of fission product yields for U-235, U-238, Pu-239, and Pu-241 at thermal, fission spectrum and 14 MeV neutron energies. APED-5398-A, General Electric Co. (Oct. 1968).
17. Burris, L.J. and I.G. Dillon. Estimation of fission product spectra in discharged fuel from fast reactors. ANL-5742, U.S. AEC, Washington, D.C. 20545 (July 1957).
18. Weaver, C.L. and E.D. Harward. Surveillance of nuclear power reactors. Public Health Rep. 82(10):899-912 October 1967).
19. Standards for Protection Against Radiation. 10 CFR 20.
20. National Committee on Radiation Protection, Recommendations "Maximum Permissible Body Burdens and Maximum Permissible Concentrations of Radionuclides in Air and in Water for Occupational Exposure." National Bureau of Standards, Handbook 69 (1959).
21. International Commission on Radiological Protection, Recommendations. "Report of Committee II on Permissible Dose for Internal Radiation (1959)." Pergamon Press, (1960).
22. Loevinger, R., E.M. Japha and G.L. Brownell. "Discrete Radioisotope Sources." in *Radiation Dosimetry*, G.J. Hine and G.L. Brownell, Ed. Academic Press, New York (1956). Chapt. 16, pp. 693-799.
23. Goussev, N.G., O.A. Kochetkov, L.M. Mikhailov, A.D. Tourkin, E.C. Trukhmanova and V.P. Filipovitch. Contribution to the setting up of standards for inert radioactive gases. Health Phys. 12:1836 (1966). (Abstract of paper given at 1st IRPA meeting-1966).
24. Dunster, H.J., and B.F. Warner. The disposal of noble gas fission products from the reprocessing of nuclear fuel. U.K. Atomic Energy Authority, Authority Health and Safety Branch Report. AHSB(RP)R 101, Conf. 691039-1 (1970).
25. Ehhalt, D., K.O Munnich, W. Roether, J. Scholch and W. Stich. Krypton-85 in the atmosphere. *Proc. 3rd Int. Conf. Peaceful Uses Atomic Energy*. Vol. 14 pp. 45-47 (1964).
26. Kigoshi, K. Krypton-85 in the atmosphere. Bull. Chem. Soc. Japan 35:1014-1016 (1962).
27. Logsdon, J.E. and R.I. Chissler. Radioactive waste discharges to the environment from nuclear power facilities. BRH/DER 70-2 Division of Environmental Radiation, EHS, BRH, Rockville, Md. 20852 (March 1970).

28. Kahn, B., R.L. Blanchard, H.L. Krieger, H.E. Kolde, D.B. Smith, A. Martin, S. Gold, W.J. Averett, W.L. Brinck, and G.J. Karches. Radiological surveillance studies at a boiling water nuclear power reactor. BRH/DER 70-1. EHS, BRH, Radiological Engineering Laboratory, Division of Environmental Radiation, 5555 Ridge Avenue, Cincinnati, Ohio 45213 (March 1970).
29. Goode, J.H. The release of tritium and krypton-85 to the atmosphere during processing of  $\text{ThO}_2\text{-UO}_2$  reactor fuel. Trans. Am. Nucl. Soc. 9:21-22 (June 1966).
30. Cochran, J.A., D.G. Smith, P.J. Magno and B. Shleien. An investigation of airborne radioactive effluent from an operating nuclear fuel reprocessing plant. BRH/NERHL 70-3. EHS, BRH, Northeastern Radiological Health Laboratory, 109 Holton Street, Winchester, Mass. 01890 (July 1970).
31. Smith, C.F. and F.F. Momyer. Studies of chemical and radiochemical composition of natural gas from the cavity produced by the Project Gasbuggy nuclear shot. Radiol. Health Data Rep. 10:281-288 (July 1969).
32. Smith, C.F. Gas quality analysis and evaluation program for Project Gasbuggy. UCRL-72153, Lawrence Radiation Laboratory, University of California, Livermore, (December 19, 1969).
33. Jacobs, D.G. and M.J. Kelly. Fifth quarterly progress report on the theoretical evaluation of consumer products from nuclearly stimulated gas wells. ORNL-TM-2862, Oak Ridge National Laboratory (Feb. 1970), AEC Contract W-7405-eng-26.
34. Jacobs, D.G., M.J. Kelly, K.E. Cowser, S.V. Kaye, P.S. Rohwer, E.G. Struxness and W.S. Snyder. Dose estimation related to peaceful uses of nuclear explosives. In: ORNL-4446, Health Physics Division Annual Progress Report for Period Ending July 31, 1969. Oak Ridge National Laboratory (Oct. 1969), pp. 26-39, AEC Contract W-7405-eng-26.
35. Smith, C.F. Jr. Project Gasbuggy gas quality analysis and evaluation program tabulation of radiochemical and chemical analytical results. UCRL-50635, Lawrence Radiation Laboratory, Univ. of California, Livermore, (17 Nov. 1969).
36. Sax, N.I., R.R. Reeves and J.D. Denny. Surveillance for krypton-85 in the atmosphere. Radiol. Health Data Rep. 10:99-101 (March 1969).
37. Delibrias, G. and C. Jehanno. Activite de l'atmosphere due au krypton 85 (activity of the atmosphere caused by krypton-85). Bull. Inform. Sci. Tech (Paris) 30:14-15 (1959).

38. Csongor, E. Radioactivity of the atmosphere. Fiz. Szemle 20:36-41 (1970). Abstract NSA 24-27244 (July 31, 1970).
39. Bannetier, R. Original use of the radioactive tracer gas krypton-85 to study the meridian atmospheric flow. J. Geophys. Res. 75:2985-2989 (May 20, 1970).
40. Haines, A.E. Isotopic studies of atmospheric methane, ethane and krypton. TID 25284, Arkansas University, Fayetteville (1968), Contract AT(40-1)-3192.
41. Shearer, E.C. Relationships among atmospheric formaldehyde, methane and krypton. TID-25286, Arkansas University, Fayetteville (1969).
42. Steinberg, M. and B. Manowitz. Recovery of fission product noble gases. Ind. Eng. Chem. 51(1):47-50 (January 1959).
43. Ostroski, K.W. and K. Jelen. On the contamination of atmospheric krypton by  $^{85}\text{Kr}$  from fission products. Nukleonika 10:61-62 (1965).
44. Shuping, R.E., C.R. Phillips and A.A. Moghissi. Low-level counting of environmental krypton-85 by liquid scintillation. SERHL 69-09, BRH Southeastern Radiological Health Laboratory, P.O. Box 61, Montgomery, Alabama 36101 (1969).
45. Shuping, R.E., C.R. Phillips and A.A. Moghissi. Low-level counting of environmental krypton-85 by liquid scintillation. Anal. Chem. 41:2082-2083 (Dec. 1969).
46. Cowser, K.E., J. Tadmor, D.G. Jacobs, F.L. Parker, W.J. Boegley, G.H. Llewellyn and D.A. Dyslin. Engineering, economic and safety evaluations. In: ORNL 4168. Health Physics Division annual progress report for period ending July 31, 1967, Oak Ridge National Laboratory. (Oct. 1967) pp. 39-48.
47. Cowser, K.E., J. Tadmor, D.G. Jacobs and W.J. Boegley, Jr. Evaluation of environmental hazards from release of  $^{85}\text{Kr}$  and  $^3\text{H}$  in an expanding nuclear fuel reprocessing industry. Health Phys. 13:943 (1967). (Abstract of paper at 13th Health Physics Society meeting).
48. Lasseart, A.H. and C. Kellershohn. Spark chambers in nuclear medicine. Nucleonics 24:56 (March 1966).
49. Federal Radiation Council. Report No. 4. "Estimates and Evaluation of Fallout in the United States from Nuclear Weapons Testing through 1962." (1963).



50. Whipple, G.H. Approaches to the calculation of limitations of nuclear detonations for peaceful purposes. In: *Proceedings for the Symposium on Public Health Aspects of Peaceful Uses of Nuclear Explosives, April 7-11, 1969*. SWRHL-82, CPEHS, ECA, BRH, South-western Radiological Health Laboratory, Las Vegas, Nevada. (1970). pp. 684-696.
51. Shleien, B. An estimate of radiation doses received by individuals living in the vicinity of a nuclear fuel reprocessing plant in 1968. BRH/NERHL 70-1. EHS, BRH, Northeastern Radiological Health Laboratory, 109 Holton Street, Winchester, Mass. 01890 (May 1970).
52. Blomeke, J.O. and J.J. Perona. Management of noble-gas fission-product wastes from reprocessing spent fuels. ORNL-TM-2677, Chemical Technology Div., Oak Ridge National Laboratory (21 Nov.1969) Contract W-7405-eng-26.
53. Perona, J.J., J.O. Blomeke and W.C.T. Stoddart. Management of noble-gas fission product wastes from reprocessing spent fuels. Trans. Am. Nucl. Soc. 12:449-50 (Nov. 1969).
54. Zindler, H. Some problems of the discharge of radioactive gases and aerosols from nuclear installations into the atmosphere. SZS-16/69 Staatliche Zentrale fuer Strahlenschutz, Berlin (East Germany) (December 1969) Abstract-NSA 24-25252 (July 15, 1970).
55. Steinberg, M. and B. Manowitz. An absorption process for recovery of fission product noble gases. BNL 493 (T-115), Brookhaven National Laboratory (Feb. 1958).
56. McIlroy, R.W., E. Glueckauf, H. J. de Nordwall and F.C.W. Pummery. The recovery of radiokrypton from dissolved waste gases by fractional extraction into solvents. *Proc. 2nd Int. Conf. Peaceful Uses of Atomic Energy*. Vol. 18, United Nations, Geneva (1958) pp. 190-199.
57. Glueckauf, E. Long-term aspect of fission product disposal. In: *Proc. 1st Int. Conf. Peaceful Uses of Atomic Energy, Geneva 1966*, Vol. 9, p. 3, United Nations, New York (1956).
58. Werner, L. Dynamic behavior of gaseous fission products in charcoal adsorber columns. DP-Report-290, Project Dragon, Atomic Energy Establishment, Winfrith, England (March 1965).
59. Kovach, J.L. Krypton-xenon adsorption on NACAR carbons. NACAR 010004, Research and Development Dept., North American Carbon, Inc., Columbus, Ohio. (December 28, 1969).
60. Underhill, D.W. An experimental analysis of fission-gas holdup beds, Nucl. Applic. Technol. 8:255-260 (March 1970).

61. Thomy, A. and X. Duval. Adsorption of simple molecules on graphite. II. Variation of the adsorption potential as a function of the number of adsorbed layers. *J. Chim. Phys.* 67:286-90 (Feb. 1970). Abstract NSA 24-36976 (September 30, 1970).
62. Anonymous. Inexpensive, effective radioactive-gas trapper. *Air and Water News* (October 19, 1970).
63. Merriman, J.R., J.H. Pashley and S.H. Smiley. Engineering development of an absorption process for the concentration and collection of krypton and xenon. Summary of progress through July 1, 1967. Rept. K-1725. Oak Ridge Gaseous Diffusion Plant (Dec. 1967). Contract W-7405-eng-26.
64. Merriman, J.R. and J.H. Pashley. Engineering development of an absorption process for the concentration and collection of krypton and xenon. Fourth summary progress report, July through December 1968. Rept. K-1786, Oak Ridge Gaseous Diffusion Plant. (April 1, 1970). Contract W-7405-eng-26.
65. Bendixsen, C.L., G.F. Offutt, and B.R. Wheeler. Rare-gas recovery facility at the ICPP. *Trans. Am. Nucl. Soc.* 12:497-498 (Nov. 1969).
66. Stern, S.A. Separation of krypton and xenon from reactor atmospheres by selective permeation. NYC-4057-1, Department of Chemical Engineering and Metallurgy, Syracuse University (1969). Contract AT (30-1)-4057.
67. Ferguson, D.E., K.B. Brown, R.G. Wymer, R.E. Blanco, M.E. Whatley, H.E. Goeller and R.E. Brookshank. Annual Progress Report for period ending May 31, 1969. ORNL-4422. Chemical Technology Division, Oak Ridge National Laboratory, October 1969. Part 4. Waste Treatment and Disposal.
68. Clark, W.E. and R.E. Blanco. Encapsulation of noble fission product gases in solid media prior to transportation and storage. ORNL-4473. Oak Ridge National Laboratory, (Feb. 1970). Contract W-7405-eng-26.
69. Reist, P.C. The disposal of radioactive krypton-85 in porous media. NYO 841-7, D. Sc. Thesis Harvard University (October 29, 1965).
70. Reist, P.C. Steady-state measurement of krypton-85-air diffusion coefficients in porous media. *Environ. Sci. Technol.* 1:566-569 (1967).
71. Davidsson, D., I. MacIntyre, A. Rapaport and J.E.S. Bradley. Determination of total fat *in vivo* using  $^{85}\text{Kr}$ . *Biochem. J.* 62:34 (1956).
72. Lesser, G.T. and G. Zak. Measurement of total body fat in man by the simultaneous absorption of two inert gases. *Ann. N.Y. Acad. Sci.* 110:40-54 (1963).

73. Hytten, F.E. Measurement of the total body fat in man with  $^{85}\text{krypton}$ . Proc. Nutr. Soc. 23:xxi (1964).
74. Hytten, F.E., K. Taylor, and N. Taggart. Measurement of total body fat in man. Clin. Sci. 31(1):111-119 (1966).
75. Lesser, G.T., W. Perl, and J.M. Steele. Determination of total body fat by absorption of an inert gas; measurements and results in normal human subjects. J. Clin. Invest. 39:1791-1806 (1960).
76. Kety, S.S. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol. Rev. 3:1-41 (1951).
77. Kety, S.S. Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med. Res. 8:223-227 (1960).
78. Sanders, R.J. and R.C. Sullivan. A method for continuous blood flow measurements using krypton-85. Surg. Forum 13:132-133 (1962).
79. Sanders, R.J. and R.C. Sullivan. Continuous regional blood flow determinations with radioactive krypton-85. J. Surg. Res. 3:185-188 (1963).
80. Hutten, H. The influence of diffusion of inert gases on the determination of blood flow by the clearance method. Scand. J. Clin. Lab. Invest. 22:Suppl. 102:II-c (1968).
81. Zierler, K.L. Basic aspects of kinetic theory as applied to tracer-distribution studies. In: *Dynamic Clinical Studies with Radioisotopes* R.M. Kniseley and W.N. Tauxe, Ed., U.S. AEC, Div. of Technical Information. (June 1964) pp. 55-79.
82. Zierler, K.L. Equations for measuring blood flow by external monitoring of radioisotopes. Circ. Res. 16:309-321 (1965).
83. Wagner, H.N., Jr. Regional blood-flow measurements with krypton-85 and xenon-133. In: *Dynamic Clinical Studies with Radioisotopes*. R.M. Kniseley and W.N. Tauxe, Ed., U.S. AEC, Div. of Technical Information. (June 1964) pp. 189-212.
84. Robertson, J.S. Theory and use of tracers in determining transfer rates in biological systems. Physiol. Rev. 37:133-153 (April 1957).
85. Rees, J.R. Radio-Isotopes and regional blood flow. Br. Heart J. 32:137-41 (March 1970).
86. Harper, A.M. Measurement of blood flow through organs and tissues with inert gases. Ann. R. Coll. Surg. Eng. 46:126-127 (March 1970).

87. Ingvar, D.H. and N.A. Lassen. Regional blood flow of the cerebral cortex determined by krypton<sup>85</sup>. *Acta. Physiol. Scand.* 54:325-338 (1962).
88. McHenry, L.C., Jr. Quantitative cerebral blood flow determination. Application of a krypton-85 desaturation technique in man. *Neurology* 14:785-793 (1964).
89. Alexander, S.C., H. Wollman, P.J. Cohen, P.E. Chase, E. Melman, and M. Behar. Krypton <sup>85</sup> and nitrous oxide uptake of the human brain during anesthesia. *Anesthesiology* 25:37-42 (1964).
90. Lassen, N.A. Blood flow of the cerebral cortex calculated from <sup>85</sup>krypton beta-clearance recorded over the exposed surface; evidence of inhomogeneity of flow. *Acta. Neurol. Scand* 41:Suppl 14:24-28 (1965).
91. Nilsson, N.J. Observations on the clearance rate of  $\beta$  radiation from krypton<sup>85</sup> dissolved in saline and injected in microliter amounts into the grey and white matter of the brain. *Acta. Neurol. Scand.* 41:Suppl. 14:53-57 (1965).
92. Lassen, N.A. and A. Klee. Cerebral blood flow determined by saturation and desaturation with krypton<sup>85</sup>: an evaluation of the validity of the inert gas method of Kety and Schmidt. *Circ. Res.* 16:26-32 (1965).
93. Ingvar, D.H., S. Cronquist, R. Ekberg, J. Riseberg and K. Hoedt-Rasmussen. Normal values of regional cerebral blood flow in man, including flow and weight estimates of gray and white matter. *Acta. Neurol. Scand.* 41:Suppl. 14:72-78 (1965).
94. Kety, S.S. Measurement of local circulation within the brain by means of inert, diffusible tracers; examination of the theory, assumptions and possible sources of error. *Acta. Neurol. Scand.* 41:Suppl 14:20-23 (1965).
95. Haggendal, E., and B. Johansson. Effects of arterial carbon dioxide tension and oxygen saturation on cerebral blood flow autoregulation in dogs. *Acta. Physiol. Scan.* 66:Suppl. 258:27-53 (1965).
96. Haggendal, E. Effects of some vasoactive drugs on the vessels of cerebral gray matter in the dog. *Acta. Physiol. Scand.* 66: Suppl. 258:55-79 (1965).
97. Kety, S.S., W.L. Landau, W.H. Freygang, Jr. L.P. Rowland, and L. Sokoloff. Estimation of regional circulation in the brain by uptake of an inert gas. *Fed. Proc.* 14:85 (1955).

98. Lewis, B.M., L. Sokoloff, W.B. Wentz, R.L. Wechsler, and S.S. Kety. Determination of cerebral blood flow using radioactive krypton. *Fed. Proc.* 14:92 (1955).
99. Lassen, N.A. and O. Munck. The cerebral blood flow in man determined by the use of radioactive krypton. *Acta. Physiol. Scand.* 33:30-49 (1955).
100. Lassen, N.A. and O. Munck. Cerebral blood flow in arteriovenous anomalies of the brain determined by the use of radioactive krypton-85. *Acta. Physchiat. Neurol. Scand.* 31:71-80 (1956).
101. Albert, S.N., C.A. Albert and J.F. Fazekas. A rapid and simple method for measuring the rate of cerebral blood flow in humans with krypton<sup>85</sup>. *J. Lab. Clin. Med.* 56:473-482 (1960).
102. Glass, H.I., A.M. Harper and M.M. Glover. The measurement of local cortical blood flow in the brain by the analysis of the clearance curve of krypton-85. *Phys. Med. Biol.* 6:65-71 (1961).
103. Harper, A.M., H.I. Glass and M.M. Glover. Measurement of blood flow in the cerebral cortex of dogs by the clearance of krypton-85. *Scott. Med. J.* 6:12-17 (1961).
104. Lassen, N.A. and D.H. Ingvar. The blood flow of the cerebral cortex determined by radioactive krypton. *Experientia* 17:42-3 (15 Jan 1961).
105. Ingvar, D.H. and N.A. Lassen. Quantitative determination of regional cerebral blood flow in man. *Lancet* 2:806-807 (1961).
106. Haggendal, E., N.J. Nilsson, and B. Norback. On the components of Kr<sup>85</sup> clearance curves from the brain of the dog. *Acta. Physiol. Scand.* 66:Suppl 258:5-25.
107. Hoedt-Rasmussen, K. Regional cerebral blood flow in man measured externally following intra-arterial administration of <sup>85</sup>Kr or <sup>133</sup>Xe dissolved in saline. *Acta. Neurol. Scand.* 41:Suppl. 14:65-68 (1965).
108. Appelgren, K.L., D.H. Lewis and E. Haggendal. A solid state needle detector for the determination of regional blood flow in the brain and the kidney by the Kr-85 clearance method. *Scand. J. Clin. Lab. Invest.* 17:511-512 (1965).
109. Fieschi, C., A. Agnoli, N. Battistini and L. Bozzao. Relationships between cerebral transit time of nondiffusible indicators and cerebral blood flow. A comparative study with krypton-85 and radio-albumin. *Experientia* 22:189-190 (1966).
110. Fieschi, C., A. Agnoli, N. Battistini and L. Bozzao. Mean transit time of a nondiffusible indicator as an index of regional cerebral blood flow. *Trans. Am. Neurol. Assoc.* 91:224-226 (1966).

111. Brock, M., D.H. Ingvar, and C.W. Sem Jacobsen. Regional blood flow in deep structures of the brain measured in acute cat experiments by means of a new beta-sensitive semiconductor needle detector. *Exp. Brain. Res.* 4:126-137 (1967).
112. Michenfelder, J.D., J.M. Messick, Jr. and R.A. Theye. Simultaneous cerebral blood flow measured by direct and indirect methods. *J. Surg. Res.* 8:475-481 (October 1968).
113. Wollman, H., S.C. Alexander, P.J. Cohen, G.W. Stephen and L.S. Zeigler. Two-compartment analysis of the blood flow in the human brain. *Acta. Neurol. Scand.* 41:Suppl 14:79-82 (1965).
114. Sokoloff, L. Cerebral blood flow measured with radioisotopes. In: *Dynamic Clinical Studies with Radioisotopes*. R.M. Kniseley and W.N. Tauxe, Ed. U.S. AEC, Div. of Technical Information. (June 1964) pp. 153-169.
115. Saito, H. Radioisotopic diagnostics. *Rinsho Byori* 17:781-89 (October 1969). Abstract NSA 24-27629 (July 31, 1970).
116. Lewis, B.M., L. Sokoloff, R.L. Wechsler, W.B. Wentz, and S.S. Kety. A method for the continuous measurement of cerebral blood flow in man by means of radioactive krypton ( $Kr^{79}$ ). *J. Clin. Invest* 39: 707-716 (1960).
117. Haggendal, E., D.H. Ingvar, N.A. Lassen, J. Nilsson, G. Norlen, I. Wickbom and N. Zwetnow. Pre- and postoperative measurements of regional cerebral blood flow in three cases of intracranial arteriovenous aneurysms. *J. Neurosurg.* 22:1-6 (1965).
118. Lassen, N.A., K. Hoedt-Rasmussen, S.C. Sorensen, E. Skinhoj, S. Cronquist, B. Bodforss, and D.H. Ingvar. Regional cerebral blood flow in man determined by krypton<sup>85</sup>. *Neurology* 13:719-727 (1963).
119. Glass, H.I. and A.M. Harper. The measurement of the partition coefficient of krypton between the brain cortex and blood by a double isotope method. *Phys. Med. Biol.* 7:335-339 (1962).
120. Chidsey, C.A. III, H.W. Fritts, Jr., A. Hardewig, D.W. Richards, and A. Cournand. Fate of radioactive krypton ( $Kr^{85}$ ) introduced intravenously in man. *J. Appl. Physiol.* 14:63-66 (1959).
121. Cornell, W.P., E. Braunwald and E.C. Brockenbrough. Use of krypton<sup>85</sup> for the measurement of cardiac output by the single-injection indicator dilution technique. *Circ. Res.* 9:984-988 (1961).
122. Rochester, D.F., J. Durand, J.O. Parker, H.W. Fritts, Jr. and R.M. Harvey. Estimation of right ventricular output in man using radioactive krypton ( $Kr^{85}$ ). *J. Clin. Invest.* 40:643-648 (1961).

123. Markason, C.R., H. Smulyan, J.F. Keighley, R.P. Cuddy and R.H. Eich. Estimation of pulmonary blood flow with the use of krypton<sup>85</sup>. *J. Lab. Clin. Med.* 60:714-722 (1962).
124. Sanders, R.J. and R.G. Sullivan. Cardiac output determination with radioactive <sup>85</sup>krypton. *J. Surg. Res.* 8:522-527 (November 1968).
125. Prys-Roberts, C. The measurement of cardiac output. *Br. J. Anesth.* 41:751-60 (Sept. 1969).
126. Hansen, A.T., B.F. Haxholdt, E. Husfeldt, N.A. Lassen, O. Munck, H.R. Sorensen and K. Winkler. Measurement of coronary blood flow and cardiac efficiency in hypothermia by use of radioactive krypton-85. *Scand. J. Clin. Lab. Invest.* 8:182-188 (1956).
127. Herd, J.A., M. Hollenberg, G.D. Thorburn, H.H. Kopald and A.C. Barger. Myocardial blood flow determined with krypton-85 in unanesthetized dogs. *Am. J. Physiol.* 203:122-124(1962)
128. Cohen, L.S., W.C. Elliott and R. Goblin. Measurement of myocardial blood flow using krypton-85. *Am. J. Physiol.* 206:997-999 (1964).
129. Johansson, B., E. Linder and T. Seeman. Collateral blood flow in the myocardium of dogs measured with krypton-85. *Acta. Physiol. Scand.* 62:263-270 (1964).
130. Ross, R.S., K. Ueda, P.R. Lichtlen and J.R. Rees. Measurement of myocardial blood flow in animals and man by selective injection of radioactive inert gas into the coronary arteries. *Circ. Res.* 15:28-41 (1964).
131. Linder, E. Measurements of normal and collateral coronary blood flow by close-arterial and intramyocardial injection of krypton-85 and xenon-133. *Acta. Physiol. Scand.* 68:Suppl 272:5-31 (1966).
132. Norman, J.C., V.H. Covelli and S. Aronow. Krypton-85 and xenon-133 myocardial flow measurements in chronically cannulated internal mammary transplants. *Surg. Forum* 18:110-111 (1967).
133. Briscoe, W.A., A. Hardewig, G. Emmanuel, P. Gurtner, D. Rochester and A. Cournand. The distribution of blood perfusion to the lung in emphysema. *Fed. Proc.* 18:59 (1959).
134. Gurtner, H.P., W.A. Briscoe and A. Cournand. Studies of the ventilation-perfusion relationships in the lungs of subjects with chronic pulmonary emphysema following a single intravenous injection of radioactive krypton (Kr-85). I. Presentation and validation of a theoretical model. *J. Clin. Invest.* 39:1080-1090 (1960).
135. Arborelius, M. Jr. Kr<sup>85</sup> in the study of pulmonary circulation during bronchospirometry. *Scand. J. Clin. Lab. Invest.* 17:253-256 (1965).

136. Arborelius, M. Jr.  $Kr^{85}$  in the study of pulmonary circulation and ventilation during unilateral hypoxia. *Scand. J. Resp. Dis. Suppl.* 62:105-111 (1966).
137. Rochester, D.F., R.A. Brown, Jr., W.A. Wichern, Jr., and H.W. Fritts, Jr. Comparison of alveolar and arterial concentrations of  $^{85}Kr$  and  $^{133}Xe$  infused intravenously in man. *J. Appl. Physiol.* 22:423-430 (March 1967).
138. Cellerino, A.F., A. Gaetini, F. Rosso and C. Banaudi. Unevenness of blood and air distribution to the lungs studied by a combined radio-krypton and helium method. *J. Nucl. Biol. Med.* 11:32-39 (1967).
139. Mellemegaard, K. The alveolar-arterial oxygen difference in chronic obstructive lung disease. *Scand. J. Resp. Dis.* 48:23-39 (1967).
140. Ranson-Bitker, B., M. Leroy Ladurie and J. Durand. Measurement of blood flow distribution of the right and left lungs by bronchspirometry and excretion of a radioactive isotope of krypton ( $Kr^{85}$ ). *Respiration* 25:395-404 (1968).
141. Brun, C., C. Crone, H.G. Davidson, J. Fabricus, A.T. Hansen, N.A. Lassen and O. Munck. Renal blood flow in anuric human subject determined by use of radioactive krypton-85. *Proc. Soc. Exp. Biol. Med.* 89:687-690 (1955).
142. Thorburn, G.D., H.H. Kopald, J.A. Herd, M. Hollenberg, C.C.C. O'Morchoe and A.C. Barger. Intrarenal distribution of nutrient blood flow determined with krypton-85 in the unanesthetized dog. *Circ. Res.* 13:290-307 (1963).
143. Bell, G., and A.M. Harper. Measurement of local blood flow in the renal cortex from the clearance of krypton-85. *J. Surg. Res.* 5:382-386 (1965).
144. Cosgrove, M.D. The effect of arterial hypoxia on the blood-flow through the renal cortex. *Br. J. Surg.* 52:613-617 (1965).
145. Ladefoged, J. and F. Pedersen. Renal blood flow in isolated kidneys measured with an electromagnetic flowmeter and by xenon-133 and krypton-85 wash-out techniques. *Pfluegers Arch.* 299:30-37 (1968).
146. MacDonald, A.G. The effect of halothane on renal cortical blood flow in normotensive and hypotensive dogs. *Br. J. Anaesth.* 41:644-655 (1969).
147. Bell, G. and A.M. Harper. Measurement of regional blood flow through the skin from the clearance of  $Kr^{85}$ . *Nature (London)* 202:704-705 (May 1964).



148. Sejrsen, P. Diffusion processes invalidating the intra-arterial  $^{85}\text{Kr}$  beta particle clearance method for measurement of skin blood flow in man. *Circ. Res.* 21:281-295 (1967).
149. Sejrsen, P. Cutaneous blood flow in man studied by freely diffusible radioactive indicators. *Scand. J. Clin. Lab. Invest.* 19:Suppl 99: 52-59 (1967).
150. Jansson, G., M. Kampp, O. Lundgren and J. Martinson. Studies on the circulation of the stomach. *Acta. Physiol. Scand.* 68:Suppl 277:91 (1966).
151. Bell, P.R.F. and T. Shelley. Gastric mucosal blood flow and acid secretion in conscious animals measured by heat clearance. *Am. J. Dig. Dis.* 13:685:696 (1968).
152. Bell, P.R.F., and C. Battersby. Effect of vasopressin (Pitressin) on gastric mucosal blood flow measured by clearance of krypton $^{85}$ . *Surgery* 66:510-514 (September 1969).
153. Lundgren, O. and M. Kampp. The washout of intraarterially injected krypton $^{85}$  from the intestine of the cat. *Experientia* 22:268-270 (1966).
154. Kampp, M., O. Lundgren and J. Sjostrand. On the components of the  $\text{Kr}^{85}$  washout curves from the small intestine of the cat. *Acta. Physiol. Scand.* 72:282-297 (1968).
155. Kampp, M., and O. Lundgren. Blood flow and flow distribution in the small intestine of the cat as analyzed by the  $\text{Kr}^{85}$  wash-out technique. *Acta. Physiol. Scand.* 72:282-297 (1968).
156. Hollenberg, M. and J. Dougherty. Liver blood flow measured by portal venous and hepatic arterial routes with  $\text{Kr}^{85}$ . *Am. J. Physiol.* 210:926-932 (1966).
157. Birtch, A.G., B.H. Casey, and R.M. Zakheim. Hepatic blood flow measured by the krypton-85 clearance technique. *Surgery* 62:174-180 (July 1967).
158. Friedman, E., H.H. Kopald, and T.R. Smith. Retinal and choroidal blood flow determined with krypton-85 in anesthetized animals. *Invest. Ophthalmol.* 3:539-546 (1964).
159. Friedman, E. and T.R. Smith. Estimation of retinal blood flow in animals. *Invest. Ophthalmol.* 4:1122-1128 (1965).
160. Holzman, G.B., H.N. Wagner, M. Ito, D. Rabinowitz and K.I. Zierler. Measurement of muscle blood flow in the human forearm with radioactive krypton and xenon. *Circulation* 30:27-34 (1964).

161. Setchell, B.P., G.M.H. Waites and G.D. Thorburn. Blood flow in the testis of the conscious ram measured with krypton<sup>85</sup>: effects of heat, catecholamines and acetylcholine. *Circ. Res.* 18:755-765 (1966).
162. Gump, F.E. and R.L. White. Determination of regional tumor blood flow by krypton-85. *Cancer* 21:871-875 (May 1968).
163. Rosen, R.G., C.E. Silver, J.C. Dougherty and M.L. Som. The pattern of rejection of dog laryngeal grafts. *Surg. Forum* 20:479-482 (1969).
164. Sanders, R.J. Use of a radioactive gas (Kr<sup>85</sup>) in diagnosis of cardiac shunts. *Proc. Soc. Exp. Biol. Med.* 97:1-4 (1958).
165. Sanders, R.J. and A.G. Morrow. The localization of circulatory shunts with inhaled krypton. A preliminary clinical report. *Bull. Johns Hopkins Hosp.* 103:27-31 (1958).
166. Long, R.T.L. and W.P. Cornell. Experimental detection of left-to-right circulatory shunts with injections of krypton<sup>85</sup>. *Soc. Exp. Biol. Med.* 101:836-838 (1959).
167. Sanders, R.J. and A.G. Morrow. The identification and quantification of left-to-right circulatory shunts. *Am. J. Med.* 26:508-516 (1959).
168. Long, R.T.L., E. Braunwald and A.G. Morrow. Intracardiac injection of radioactive krypton. Clinical applications of new methods for characterization of circulatory shunts. *Circulation* 21:1126-1133 (1960).
169. Braunwald, E., A. Goldblatt, R.T.L. Long and A.G. Morrow. The krypton<sup>85</sup> inhalation test for the detection of left-to-right shunts. *Br. Heart J.* 24:47-54 (1962).
170. Selzer, A., R.W. Popper and F. Mintz. Evaluation of left-to-right cardiac shunts. *J. Cardiovasc. Surg.* 5:285-291 (1964).
171. Weitzman, D., J. McAlister and A. Houlder. Localization of left-to-right shunts by radioactive krypton. *Br. Heart J.* 26:577-583 (1964).
172. Singleton, R.T., D.H. Dembo and L. Scherlis. Krypton-85 in the detection of intracardiac left-to-right-shunts. *Circulation* 32:134-137 (1965).
173. Bekheit, S., J.G. Murtagh, E. Fletcher and P.F. Binnion. Comparison between oximetry and <sup>85</sup>krypton studies in left-to-right cardiac shunts. *Ir. J. Med. Sci.* 8:169-176 (1969).

174. Long, R.T.L., J.A. Waldhausen, W.P. Cornell and R.J. Sanders. Detection of right-to-left shunts: A new method utilizing injections of krypton<sup>85</sup>. *Proc. Soc. Exp. Biol. Med.* 102:456-458 (1959).
175. Fritts, H.W. Jr., A. Hardewig, D.F. Rochester, J. Durand and A. Cournand. Estimation of pulmonary arteriovenous shunt-flow using intravenous injections of T-1824 dye and Kr<sup>85</sup>. *J. Clin. Invest.* 39:1841-1850 (1960).
176. Mellempgaard, K., N.A. Lassen and J. Georg. Right-to-left shunt in normal man determined by the use of tritium and krypton-85. *J. Appl. Physiol.* 17:778-782 (1962).
177. Zaky, H.A., A.R. El-Heneidy and M. Khalil. Use of krypton-85 in the study of hypoxia in porto-pulmonary bilharziasis (Shistosomiasis). *Br. Med. J.* 5389:1021-1024 (1964).
178. Cleempoel, H., P. Mercenier, R. Bernard, M. Lebedelle and J. Lequime. The krypton-85 method in the detection of pulmonary arterio-venous shunts. *Cardiologia* 51:55-63 (1967).
179. Sanders, R.J. and L.J. Hellerstein. The diagnosis of right-to-left shunts with krypton-85. *J. Surg. Res.* 9:441-448 (July 1969).
180. Long, R.T.L., C.R. Lombardo and E. Braunwald. Use of radioactive krypton and cardio-green dilution curves in the detection of experimental portal-systemic venous shunts. *Ann. Surg.* 151:146-152 (1960).
181. Cellerino, A.F. and R. Catolla-Cavalcanti. The slow radioactive krypton method using a breath-by-breath counting system in measurement of blood and gas distribution in separated lungs. *Panminerva Med.* 7:427-433 (1965).
182. Byun, H.H., G. Albrecht, G.W. Holmes and R.S. Landauer. Pulmonary function test using krypton-85. *J. Nucl. Med.* 4:345-358 (1963).
183. West, J.B. The use of radioactive materials in the study of lung function. Medical Monograph No. 1, Radiochemical Centre, Amersham England (1967).
184. Dibdin, G.H. The internal surface and pore structure of teeth. *J. Dent. Res.* 48:771-776 (Sept.-Oct. 1969).
185. Robert, L., B. Robert, J. Medema and J.P.W. Houtman. Surface areas of elastin samples determined by krypton-85 adsorption. *Biochim. Biophys. Acta* 214:235-237 (1970).
186. Geller, E.I., F.X. Worden, G. Cassidy, and C.Y. Bartholomew. Personnel protection program for industrial use of krypton-85. *Am. Ind. Hyg. Assoc. J.* 22:403-408 (1961).

187. Ellis, W.R. and B.W. Seatonberry. A radioisotope method for locating points of entry of carbon monoxide into the cabin of an aircraft. *Int. J. Appl. Radiat. Isot.* 17:81-84 (1966).
188. Tsivoglou, E.C., J.B. Cohen, S.D. Shearer and P.J. Godsil. Tracer measurement of stream aeration. *J. Water Pollut. Contr. Fed.* 40:285-305.
189. Corn, M. and T.L. Montgomery. Atmospheric particulates: specific surface areas and densities. *Science* 159:1350-1351 (1968).
190. Fries, B.A. Flow rate measurements of condensable gases by the carrier-gas method. *Int. J. Appl. Radiat. Isot.* 19:39-42 (1968).
191. Robertson, J.B. Diffusion from a gaseous source in a porous medium a field and theoretical investigation. U.S. Geol. Surv., Prof. Pap. 650-D:265-273 (1969).
192. Martin, J.E. The correlation of wind tunnel and field measurements of gas diffusion using krypton-85 as a tracer. Ph.D. Thesis, University of Michigan, 1965.
193. Martin, J.E. Methods of using  $^{85}\text{Kr}$  as a tracer to study gas emission from nuclear facilities. *Health Phys.* 15:175 (Aug. 1968). Abstract of paper given at 1968 Health Physics Society meeting.
194. Ludwick, J.D., J.J. Lashock, R.E. Connaly and P.W. Nickola. Automatic real time air monitoring of  $^{85}\text{Kr}$  utilizing the 4096 memory of a multi-parameter analyzer. *Rev. Sci. Instrum.* 39:853-859 (June 1968).
195. Nikola, P.W., J.V. Ramsdell, Jr., and J.D. Ludwick. Detailed time-histories of concentrations resulting from puff and short-period releases of an inert radioactive gas: a volume of atmospheric diffusion data. BNWL-1272. Battelle-Northwest, Richland, Wash. Pacific Northwest Lab., (Feb. 1970). Contract AT-(45-1)-1830.
196. Nikola, P.W., J.V. Ramsdell and J.D. Ludwick. Real time histories of diffusing plumes and puffs determined from use of an inert gas tracer system. BNWL 1307 (pt. 1), pp. 6-10, Battelle-Northwest, Richland, Wash. Pacific Northwest Lab. (1970).
197. Nikola, P.W. Measurements of the transport speed and physical dimensions of a diffusing puff of a gaseous tracer in the atmosphere. BNWL-1307 (pt. 1) pp. 10-14, Battelle-Northwest, Richland, Washington, Pacific Northwest Lab. (1970).
198. Eddy, W.J. Jr. Evaluation of cracks in turbine-blade leading edge by use of  $^{85}\text{Kr}$  gas. *Isotop. Radiat. Technol.* 7:277-285 (Spring 1970).

199. Jech, C. An autoradiographic technique for observing channeled penetration of low energy ions. *Appl. Phys. Lett.* 15:248-50 (Oct. 15, 1969).
200. Jech, C. and R. Kelly. Studies on bombardment-induced disorder. II. Formation of ion-bombardment-induced disorder in zircon, corundum, and diamond. *J. Phys. Chem. Solids* 31:41-8 (Jan. 1970). Abstract NSA 24-21861 (June 15, 1970).
201. Lukac, P. Device for preparing radioactive kryptonates by ion bombardment. *Radiochem. Radioanal. Lett.* 3:121-127 (12 March 1970). Abstract NSA 24-21861 (June 15, 1970).
202. Toelgyessy, J., V. Jesenak, and E. Koval. Possible uses of radioactive kryptonates of silver in chemical analysis. *J. Radioanal. Chem.* 4:13-19 (Jan. 1970) (In German). Abstract NSA 24-16417, May 15, 1970.
203. Hendrickson, M.M. The dose from  $^{85}\text{Kr}$  released to the earth's atmosphere. BNWL-SA-3233A. Battelle Memorial Institute, Pacific Northwest Laboratory, Richland, Washington 99352. (July 1970).
204. Hendrickson, M.M. The eventual whole body exposure rate from  $^{85}\text{Kr}$  released to the atmosphere. Battelle Memorial Institute, Pacific Northwest Laboratory, Richland, Washington 99352. (July 13, 1970).
205. Russell, J.L. and F.L. Galpin. Estimated doses to the whole body and to the lungs from radioactive noble gases using the MIRD methodology. EPA, Office of Radiation Programs, Division of Technology Assessment, Rockville, Maryland 20852. (In draft July 1971).
206. Lassen, N.A. Assessment of tissue radiation dose in clinical use of radioactive inert gases, with examples of absorbed doses from  $^3\text{H}_2$ ,  $^{85}\text{Kr}$  and  $^{133}\text{Xe}$ . *Minerva Nucleare* 8:211-217 (Jul.-Aug. 1964).
207. ICRP Publication 9. Recommendations of the International Commission on Radiological Protection (Adopted Sept. 17, 1965). Pergamon Press (1966).
208. Bucheit, R.G., H.R. Schreiner and G.F. Doebbler. Growth responses of *Neurospora crassa* to increased partial pressures of the noble gases and nitrogen. *J. Bacteriol.* 21:622-627 (1966).
209. Sears, D.F. and S.M. Gittleson. Cellular narcosis of *Paramecium multimicronucleatum* by xenon and other chemically inert gases. *J. Protozool.* 11:538-546 (1964).
210. Gottlieb, S.F., A. Cymerman and A.V. Metz. Effect of xenon, krypton and nitrous oxide on sodium active transport through frog skin with additional observations on sciatic nerve conduction. *Aerosp. Med.* 39:449-453 (May 1968).

211. Gottlieb, S.F. and J.M. Weatherly. Physiological effects of the noble gases on frog sciatic nerve and gastrocnemius muscle. *Am. J. Physiol.* 208:407-411, (1965).
212. Schreiner, H.R. General biological significance of metabolically inert gases. *Int. Anesthesiol. Clin.* 1:919-926 (1963).
213. Evans, J.C., T.W. Roberts and L.R. Orkin. Modification of radio-sensitivity of mice by inert gases and nitrous oxide. *Radiat. Res.* 21:243-255 (1964).
214. Markoe, A.M., R. Anigstein and R.J. Schulz. Effects of inert gases and nitrous oxide on the radiation sensitivity of HeLa cells. *Phys. Med. Biol.* 15:200 (Jan. 1970).
215. Schreiner, H.R. General biological effects of the helium-xenon series of elements. *Fed. Proc.* 27:872-878 (1968).
216. Williams, K.D. A rapid determination of the specific activity of krypton-85 in pressurized cylinders. *J. Nucl. Med.* 5:913-919 (1964).
217. Smith, D.G., J.A. Cochran and B. Shleien. Calibration and initial field testing of  $^{85}\text{Kr}$  detectors for environmental monitoring around a nuclear fuel reprocessing facility. BRH/NERHL 70-4, EHS, BRH, Northeastern Radiological Health Laboratory, 109 Holton Street, Winchester, Mass. 01890 (November 1970).
218. Anonymous. Continuous sampler monitor (CMS). Cape-1985, Idaho Nuclear Corp., Idaho Falls (10 Sept. 1969). Abstract NSA 24-25169 (July 15, 1970).
219. Tolbert, B.M. Ionization chamber assay of radioactive gases. UCRL 3499, University of California, Radiation Laboratory, Berkeley California, (March 5, 1956).
220. Dupuis, M.C., G. Charrier, C. Alba and D. Massimino. Possibilities of gas-phase radiochromatography application to permanent gas analysis. CEA-R-3879. Commissariat a l'Energie Atomique, Bruyeres-le-Chatel (France) Centre d'Etudes. (Jan 1970) (French). Abstract NSA 24-38744 (Oct. 15, 1970).
221. Horrocks, D.L. and M.H. Studier. Determination of radioactive noble gases with a liquid scintillator. *Anal. Chem.* 36:2077-2079 (1964).
222. Curtis, M.L., S.L. Ness and L.L. Bentz. Simple technique for rapid analysis of radioactive gases by liquid scintillation counting. *Anal. Chem.* 38:636-637 (1966).
223. Sax, N.I., J.D. Denny and R.R. Reeves. Modified scintillation counting technique for determination of low level krypton-85. *Anal. Chem.* 40:1915-1916 (1968).

224. Voice, E.H. A low-level measurement of  $^{85}\text{Kr}$ . DP-Report-109, Project Dragon, Atomic Energy Establishment, Winfrith, England (Aug. 1962).
225. Ueda, H., Y. Sasaki, M. Iio, S. Kaihara and I. Ito. Catheter semiconductor radiation detector for continuous measurement of cardiac output. J. Nucl. Med. 10:713-721 (Dec. 1969).
226. Terrill, J.G. Jr., C.L. Weaver, E.D. Harward and D.R. Smith. Environmental surveillance of nuclear facilities. Nucl. Safety 9:143-149 (Mar-Apr, 1968).
227. Sheibley, D.W. A simple method for determination of fission gases trapped in irradiated fuel forms. Anal. Chem. 42:142-3 (Jan. 1970).
228. Davis, M.A. and J. Shapiro. Calibration of a GM detector to measure  $^{85}\text{Kr}$  in air by immersion in a standardized  $^{204}\text{Tl}$  solution. Health Phys. 13:907-910 (1967).
229. Jennison, E. Fission gas collection and trace gas analysis. Progr. Nucl. Energy, Ser. IX; 10:225-54 (1970).
230. Flygare, J.K., G. Wehmann, A.R. Harbertson and C.W. Sill. A method for the collection and identification of radioactive xenon and krypton. TID 7593, Health and Safety Division, AEC, Idaho Falls, (Oct. 1960) p. 18-25.
231. Mantel, J., K.J. Cook and K.E. Corrigan. Radioactive krypton and xenon trapping by cryogenic technics. Radiology 90:590-591 (1968).
232. Lengweiler, H. Experiments on separation procedure for krypton and xenon in connection with Pluto Loop radiochemical sampling. DP-Report-89. Project Dragon, Atomic Energy Establishment, Winfrith, England (Apr. 1962). Abstract NSA 24-36166 (Sept. 30, 1970).
233. Charrier, G. Separation and determination of krypton and xenon by gas phase radiochromatography. CEA-R-3889, Commissariat a l'Energie Atomique, Bruyeres-le-Chatel (France). Centre d'Etudes. (March 1970). Abstract NSA 24-26994, (July 31, 1970).
234. Aubeau, R., L. Champeix and (Mme) J. Reiss. Separation et dosage du krypton et du xenon par chromatographie en phase gazeuse. Application aux gaz de fission. J. Chromatog. 6:209-219 (1961).

## APPENDIX A

### ABSORPTION OF KR INTO THE BODY

#### 1. SOLUBILITY OF $^{85}\text{Kr}$ IN VARIOUS MATERIALS: PARTITION COEFFICIENTS

(General references 1,2)

Gas solubility data in the literature are frequently expressed in terms of either the Bunsen solubility coefficient ( $\alpha$ ) or the Ostwald solubility coefficient (L). In component units:

$$\alpha = \frac{V_o(a) P_o}{V P}$$

where:  $V_o(a)$  = volume of gas absorbed  
 $V$  = volume of absorbing fluid  
 $P_o$  = 760 mm Hg  
 $P$  = partial pressure of the gas being absorbed in mm Hg

and  $L = \alpha T/T_o$

where:  $T_o$  = 273° K  
 $T$  = 273° K + temperature at which gas is absorbed in °C

The Ostwald coefficient, L, is also commonly called the partition coefficient and is sometimes designated as  $\lambda$ . As commonly used, a partition coefficient will be written as  $\lambda$  medium 1:medium 2 (example  $\lambda$  blood:air) and is the ratio of the volume concentration in medium 1 to the volume concentration in medium 2 at equilibrium. If  $\lambda$  blood:air = 0.06, and the air concentration is  $1 \mu\text{Ci}/\text{cm}^3$ , the blood concentration will be  $1 \mu\text{Ci}/\text{cm}^3 \times 0.06 = 0.06 \mu\text{Ci}/\text{cm}^3$ .

The solubility of Kr has been determined *in vitro*, usually with degassed solvents, for a number of solvents and solutions. These data are summarized in Table A-1.

#### 2. IN VIVO PARTITION COEFFICIENTS

The tissue:air partition coefficient ( $\lambda$ ) for an organ or system is given by:

where:  $\lambda$  tissue:air =  $\sum (\lambda_i \text{ tissue:blood} \times f_i)$   $\lambda$  blood:air  
 $\lambda_i$  = tissue:blood partition coefficient for component i  
 $f_i$  = the fraction of the organ or system made up of component i



TABLE A-1. SOLUBILITY COEFFICIENTS FOR  $^{85}\text{Kr}$  IN VARIOUS SOLVENTS<sup>a</sup>

Solvent	Temp(°C)	Bunsen Coefficient	(ref)	Ostwald Coefficient	
Olive oil	45	0.3844	(13)	0.4477	(13)
	37	0.4031	(13)	0.4581	(13)
		0.43	(35)		
		0.44	(36)		
	30	0.4225	(13)	0.4688	(13)
	25	0.4376	(13)	0.4746	(13)
	22	0.44	(35)		
	45	0.0441	(14)		
Water	45	0.0441	(14)		
	37	0.0481	(14)	0.0499	(38)
		0.045	(37, 35)		
	30	0.0539	(14)		
	25	0.0581	(14)		
	22	0.059	(35)		
Saline soln.	45	0.0411	(14)		
	37	0.0444	(14)		
	30	0.0499	(14)		
	25	0.0542	(14)		
$\beta$ -albumin	37	0.0195	(12)		
	30	0.0412	(12)		
	25	0.0624	(12)		
Hemoglobin soln. (15.4%)	37	0.0247	(12)		
Blood	37	0.0455	(12)	0.0517	(12)
				0.06	(39)
Muscle homogenate	37	0.0439	(12)		
	30	0.0501	(12)		
	25	0.0549	(12)		
Brain homogenate	37	0.0454	(12)		
	30	0.0517	(12)		
	25	0.0572	(12)		

Solvent	Temp(°C)	Bunsen Coefficient	(ref)	Ostwald Coefficient	
Human fat	45	0.3878	(13)	0.4516	(13)
		0.3875	(13)	0.4513	(13)
	37	0.4071	(13)	0.4626	(13)
		0.4062	(13)	0.4617	(13)
		0.420	(36)	0.425	(41)
	30	0.414	(36)		
		0.4258	(13)	0.4725	(13)
		0.4247	(13)	0.4713	(13)
	25	0.4412	(13)	0.4816	(13)
		0.4404	(13)	0.4807	(13)
Dog fat	45	0.3853	(13)	0.4426	(13)
	37	0.4031	(13)	0.4581	(13)
	30	0.4225	(13)	0.4721	(13)
	25	0.4364	(13)	0.4764	(13)
Rat fat	45	0.3847	(13)	0.4481	(13)
	37	0.4037	(13)	0.4588	(13)
	30	0.4219	(13)	0.4755	(13)
	25	0.4363	(13)	0.4762	(13)
Toluene base liquid scint. cocktail	-15	0.9	(40)		

<sup>a</sup> Additional <sup>85</sup>Kr solubility data in a wide variety of chemicals may be found in references (2, 42-46).

If the tissue components, their relative fractions, and their Ostwald coefficients are known, the tissue:air coefficient can be calculated. In practice this is rarely the case and the coefficient is either determined for the tissue by a dual isotope method such as that of Glass and Harper (3), or, in many cases, estimated to be the same as that for blood. A partial listing of the experimentally determined tissue:air or tissue:blood partition coefficients for  $^{85}\text{Kr}$  follows:

<u>Tissue</u>	<u>Part</u>	<u>Tissue:Blood</u>	<u>Tissue:Air</u>	<u>Reference</u>
Brain	Cortex	0.92 (Hc=50)		4,5
	White	1.26 (Hc=50)		4,5
Kidney	Cortex	1.0		6
		0.96		7
	Medulla	1.0		6
Fat		9		6
			0.54	8
		5		5
Liver		1.06		9
		1.04		5
Eye	Retina	1.0		5
Skeletal muscle		1.0		5
Testis		0.85		5,10
Blood			0.05-0.06	Various

Because the coefficients are so similar, Lassen (8), one of the pioneers in this work, normally uses a tissue:air coefficient of 0.06 for all tissues except fat for which he uses 0.54 ( $9 \times 0.06$ ). The only significant variable, for most purposes, is the fat content of the tissue or body being studied. Lassen (8) uses a whole-body tissue:air coefficient of 0.11 for lean people, 0.20 for normal weight people, and 0.30 for obese people. The calculated coefficient for standard man is 0.163.

Whole-body partition coefficients and kinetic parameters for female Rochester Wistar rats, weighing about 250 grams, were experimentally determined by saturating the animals with  $^{85}\text{Kr}$  in a closed exposure system for 12 1/2 or 33 1/2 hours, then whole-body counting in a 3- x 5-inch NaI well crystal until the count reached background (about 12 hours). The average seven determinations on four animals was 0.0921 (S. D. = 0.0188). The coefficient for one animal that died during the 12 1/2 hour run, determined by counting component pieces, was 0.0958. The value predicted for rats of 320 grams, using the tissue composition data of Caster, *et al.* (11), and the solubility data of Yeh and Peterson (12, 13, 14) was 0.076. Using Lassen's coefficients (8) and the Caster fat fraction of 0.0708 of the body weight, a value of 0.094 would be predicted.

### 3. KINETICS OF $^{85}\text{Kr}$ ABSORPTION AND DESORPTION IN THE BODY

The rate of absorption of  $^{85}\text{Kr}$  into the tissues of the body during exposure and desorption after exposure or injection of the isotope is a complex function of the tissue:blood partition coefficients and, particularly, the blood circulation in the tissue in question. The curves obtained will have as many exponential components as there are differently perfused elements in the tissue being studied. Kety (1) has discussed the kinetics involved in detail. For a single tissue, with the concentration in alveolar air considered constant and blood-tissue diffusion time considered negligible (actually less than 1 sec.), the following equations apply:

$$\text{Saturation: } C_i = \lambda_i C_a' (1 - e^{-kt})$$

$$\text{Desaturation: } C_i = C_{i(0)} e^{-kt}$$

where:  $C_i$  = concentration in tissue  $i$  at time  $t$ ,  $\mu\text{Ci}/\text{cm}^3$

$\lambda_i$  = tissue:air partition coefficient

$C_a'$  = concentration in air,  $\mu\text{Ci}/\text{cm}^3$

$k = F_i/V_i$  where  $F_i$  = blood flow rate in tissue  $i$ , and  $V_i$  = volume of tissue  $i$

The quantity of gas in the tissue ( $Q_i$ ) =  $V_i C_i$  or  $Q_i = V_i \lambda_i C_a' (1 - e^{-kt})$  in saturation.  $Q_{i(\infty)} = V_i \lambda_i C_a'$ . For the whole body, or a multiple compartment tissue,  $Q = Q_{1(\infty)} (1 - e^{-k_1 t}) + Q_{2(\infty)} (1 - e^{-k_2 t}) + \dots + Q_{n(\infty)} (1 - e^{-k_n t})$  in saturation and similarly for desaturation:

$$Q = Q_{1(0)} e^{-k_1 t} + Q_{2(0)} e^{-k_2 t} + \dots + Q_{n(0)} e^{-k_n t}$$

Most investigators have found at least 2-4 components in their saturation and desaturation curves with  $^{85}\text{Kr}$ . The exceptions have been when a GM counter was being used to count the beta emissions from a homogenous surface layer thicker than the maximum beta range such as the cerebral cortex or renal cortex. Wherever NaI detectors were used or heterogenous tissues were counted, monoexponential curves were rarely found (15-32).

Experimental observations in dogs, cats, and humans (4, 6, 7, 10, 15-32) indicate that there are three or four groups of similarly perfused tissues that can be treated as compartments for purposes of whole-body analyses. There is a fast component, with  $T_{1/2}$  from 0.04-0.8 min, which may be due to arterial blood content. Three slower compartments are usually seen with average half times of about 2.5 minutes, 7.5 minutes, and 20-30 minutes (range of 1-5, 5-10 and 11-180 minutes). Anything that changes blood flow rate can radically change the observed compartmental half-times in saturation or desaturation and can even cause an apparent change in the number of compartments observed.

Lesser and Zak (33) proposed a three-compartment parallel model consisting of:

1. Rapidly perfused lean tissues such as the heart, brain, kidneys, etc.
2. More slowly perfused lean tissues such as resting muscle, skin, connective tissue, etc.
3. Adipose tissue.

While this is obviously an oversimplification, it will suffice for the purpose of this discussion.

The relative contribution of the various compartments to the whole-body burden at full saturation ( $Q_i$ ) is determined by the size of the compartment,  $V_i$ , the tissue:air partition coefficient,  $\lambda_i$ , and the gas concentration in air provided the factors are known. Hypothetical saturation and desaturation curves for standard man are shown in Figure A-1.

Experimental saturation/desaturation data are usually plotted on semilog paper and resolved into components graphically. Computer curve stripping techniques have been reported (34).

Desaturation data obtained with female rats in the experiments previously mentioned were resolved by a stripping technique. The original curve and three components for a rat saturated in an  $^{85}\text{Kr}$  mixture for 12 1/2 hours are shown in Figure A-2. The component halftimes were 3.75 minutes, 22.6 minutes, and 94.2 minutes and the corresponding fractions of total activity were 0.248, 0.647 and 0.105. A second experiment, using the same animal and saturation time of 33 1/2 hours, resulted in the two-compartment curves shown in Figure A-3 with halftimes and fractional activities of 15.7 minutes: 0.89, and 85 min: 0.11, respectively. The cause of the differences in curves obtained is not known but may be stress from prolonged exposure to radiation ( $\sim 3000$  rad) and chamber dryness resulting in increased respiration and circulation which increased the rate of gas exchange from the tissue to air. Another possibility is greater loss of stored fat in the longer experiment. A greater weight loss was noted; but, since no food or water balance was kept, the loss could not be unequivocally attributed to fat loss.




Figure A-1. Hypothetical  $^{85}\text{Kr}$  saturation and desaturation curves for standard man.




Figure A-2. Experimental  $^{85}\text{Kr}$  desaturation curves in rat - short exposure.




Figure A-3. Experimental  $^{85}\text{Kr}$  desaturation curves in rat - long exposure.

# APPENDIX REFERENCES

1. Kety, S.S. The theory and applications of the exchange of inert gas at the lungs and tissues. *Pharmacol. Rev.* 3:1-41 (1951).
2. Steinberg, M. and B. Manowitz. An absorption process for recovery of fission product noble gases. BNL 493(T-115). Brookhaven National Laboratory (Feb. 1958).
3. Glass, H.I. and A.M. Harper. The measurement of the partition coefficient of krypton between the brain cortex and blood by a double isotope method. *Phys. Med. Biol.* 7:335-339 (1962).
4. Ingvar, D.H. and N.A. Lassen. Regional blood flow of the cerebral cortex determined by krypton<sup>85</sup>. *Acta Physiol. Scand.* 54:325-338 (1962).
5. Kampp, M. and O. Lundgren. Blood flow and flow distribution in the small intestine of the cat as analyzed by the Kr<sup>85</sup> wash-out technique. *Acta Physiol. Scand.* 72:282-297 (1968).
6. Thorburn, G.D., H.H. Kopald, J.A. Herd, M. Hollenberg, C.C.C. O'Morchoe and A.C. Barger. Intrarenal distribution of nutrient blood flow determined with krypton<sup>85</sup> in the unanesthetized dog. *Circ. Res.* 13:290-307 (1965).
7. Bell, G. and A.M. Harper. Measurement of local blood flow in the renal cortex from the clearance of krypton<sup>85</sup>. *J. Surg. Res.* 5: 382-386 (1965).
8. Lassen, N.A. Assessment of tissue radiation dose in clinical use of radioactive inert gases, with examples of absorbed doses from <sup>3</sup>H<sub>2</sub>, <sup>85</sup>Kr and <sup>133</sup>Xe. *Minerva Nucleare* 8:211-217 (Jul.-Aug. 1964).
9. Hollenberg, M. and J. Dougherty. Liver blood flow measured by portal venous and hepatic arterial routes with Kr<sup>85</sup>. *Am. J. Physiol.* 210: 926-932 (1966).
10. Setchell, B.P., G.M.H. Waites and G.D. Thorburn. Blood flow in the testis of the conscious ram measured with krypton 85: effects of heat, catecholamines and acetylcholine. *Circ. Res.* 18:755-765 (1966).
11. Caster, W.O., J. Poncelet, A.B. Simon and W.D. Armstrong. Tissue weights of the rat. I. Normal values determined by dissection and chemical methods II. Changes following 700 r total body X-irradiation *Proc. Soc. Exp. Biol. Med.* 91:122-129 (1956).
12. Yeh, S.Y. and R.F. Peterson. Solubility of krypton and xenon in blood, protein solutions and tissue homogenates. *J. Appl. Physiol.* 20:1041-1047 (1965).



13. Yeh, S.Y. and R.F. Peterson. Solubility of carbon dioxide, krypton and xenon in lipids. *J. Pharm. Sci.* 52:433-458 (1963).
14. Yeh, S.Y. and R.F. Peterson. Solubility of carbon dioxide, krypton, and xenon in aqueous solution. *J. Pharm. Sci.* 53:822-824 (1964).
15. Glass, H.I., A.M. Harper, and M.M. Glover. The measurement of local cortical blood flow in the brain by the analysis of the clearance curve of krypton-85. *Phys. Med. Biol.* 6:65-71 (1961).
16. Lassen, N.A. Blood flow of the cerebral cortex calculated from <sup>85</sup>krypton-beta-clearance recorded over the exposed surface; evidence of inhomogeneity of flow. *Acta Neurol. Scand.* 41:24-28 (1965).
17. Haggendal, E. and B. Johansson. Effects of arterial carbon dioxide tension and oxygen saturation on cerebral blood flow autoregulation in dogs. *Acta Physiol. Scand.* 66:Suppl. 258:27-53 (1965).
18. Haggendal, E. Effects of some vasoactive drugs on the vessels of cerebral grey matter in the dog. *Acta Physiol. Scand.* 66:Suppl. 258:55-79 (1965).
19. Haggendal, E., N.J. Nilsson and B. Norback. On the components of Kr<sup>85</sup> clearance curves from the brain of the dog. *Acta Physiol. Scand.* 258:5-25 (1965).
20. Brock, M., D.H. Ingvar and C.W. Sem Jacobsen. Regional blood flow in deep structures of the brain measured in acute cat experiments by means of a new beta-sensitive semiconductor needle detector. *Exp. Brain. Res.* 4:126-137 (1967).
21. Herd, J.A., M. Hollenberg, G.D. Thorburn, H.H. Kopald and A.C. Barger. Myocardial blood flow determined with krypton 85 in unanesthetized dogs. *Am. J. Physiol.* 203:122-124 (1962).
22. Cohen, L.S., W.C. Elliott and R. Goblin. Measurement of myocardial blood flow using krypton 85. *Am. J. Physiol.* 206:997-999 (1964).
23. Ross, R.S., K. Ueda, P.R. Lichtlen and J.R. Rees. Measurement of myocardial blood flow in animals and man by selective injection of radioactive inert gas into the coronary arteries. *Circ. Res.* 15:28-41 (1964).
24. Cosgrove, M.D. The effect of arterial hypoxia on the blood-flow through the renal cortex. *Br. J. Surg.* 52:613-617 (1965).
25. MacDonald, A.G. The effect of halothane on renal cortical blood flow in normotensive and hypotensive dogs. *Br. J. Anaesth.* 41:704-705 (1964).

26. Bell, G. and A.M. Harper. Measurement of regional blood flow through the skin from the clearance of krypton-85. *Nature (Lond)* 202:704-705 (1964).
27. Jansson, G., M. Kampp, O. Lundgren and J. Martinson. Studies on the circulation of the stomach. *Acta Physiol. Scand.* 68:Suppl 277:91 (1966).
28. Lundgren, O. and M. Kampp. The washout of intraarterially injected krypton<sup>85</sup> from the intestine of the cat. *Experientia* 22:268-270 (1966).
29. Birtch, A.G., B.H. Casey and R.M. Zakheim. Hepatic blood flow measured by the krypton-85 clearance technique. *Surgery* 62:174-180 (July 1967).
30. Friedman, E., H.H. Kopald and T.R. Smith. Retinal and chroidal blood flow determined with krypton-85 in anesthetized animals. *Invest. Ophthalmol.* 3:539-546 (1964).
31. Holzman, G.B., H.N. Wagner, M. Iio, D. Rabinowitz and K.I. Zierler. Measurement of muscle blood flow in the human forearm with radioactive krypton and xenon. *Circulation* 30:27-34 (1964).
32. Tobias, C.A., H.B. Jones, J.H. Lawrence and J.G. Hamilton. The uptake and elimination of krypton and other inert gases by the human body. *J. Clin. Invest.* 28:1375-1385 (1949).
33. Lesser, G.T. and G. Zak. Measurement of total body fat in man by the simultaneous absorption of two inert gases. *Ann. N.Y. Acad. Sci.* 110:40-54 (1963).
34. Sveinsdottir, E. Clearance curves of Kr<sup>85</sup> or Xe<sup>133</sup> considered as a sum of mono-exponential outwash functions. Description of a computer program for the simple case of only two compartments. *Acta Neurol. Scand.* 41:Suppl. 14:69-71 (1965).
35. Lawrence, J.H., W.F. Loomis, C.A. Tobias, and F.H. Turpin. Preliminary observations on the narcotic effect of xenon with a review of values for solubilities of gases in water and oils. *J. Physiol.* 105:197-204 (1946).
36. Masson, M.B.R. and K. Taylor. Solubility of krypton-85 in olive oil and human fat. *Phys. Med. Biol.* 12:93-98 (1967).
37. Lawrie, J.A., H.R. Schreiner and C.W. Cowley. Controlled atmosphere incubator for physiological studies involving the rare gases. *J. Appl. Physiol.* 19:330-332 (1964).

38. Hardewig, A., D.F. Rochester and W.A. Briscoe. Measurement of solubility coefficients of krypton in water, plasma, and human blood, using radioactive  $\text{Kr}^{85}$ . J. Appl. Physiol. 15:723-725 (1960).
39. Morrison, T.J. and N.B. Johnson. Solubilities of the inert gases in water. J. Chem. Soc. 1954:3441-3446 (1954).
40. Horrocks, D.L. and M.H. Studier. Determination of radioactive noble gases with a liquid scintillator. Anal. Chem. 36:2077-2079 (1964).
41. Hytten, F.E., K. Taylor and N. Taggart. Measurement of total body fat in man by absorption of  $^{85}\text{Kr}$ . Clin. Sci. 31:111-119 (1966).
42. Clever, H.L. The solubility of argon and krypton in p-xylene and p-xylene-p-dihalobenzene mixtures at  $30^{\circ}$ . J. Phys. Chem. 61:1082-1083 (1957).
43. Clever, H.L., J.H. Saylor and P.M. Gross. The solubility of helium, neon, argon, krypton and xenon in methylcyclohexane and perfluoromethylcyclohexane. J. Phys. Chem. 62:89-91 (1958).
44. Clever, H.L., R. Battino, J.H. Saylor and P.M. Gross. The solubility of helium, neon, argon and krypton in some hydrocarbon solvents. J. Phys. Chem. 61:1078-1082 (1957).
45. Reed, E.L. and J.J. Droher. Solubility and diffusivity of inert gases in liquid sodium, potassium, and NaK. LMEC-69-36, Atomic International, Canoga Park, Calif. Liquid Metal Engineering Center, (31 Jan. 1970), (Contract AT(04-3) -700).
46. Yamamoto, Y. and H. Takeda. Solubility of  $^{85}\text{Kr}$  in some organic solvents. Tokyo Daigaku Kogakubu Kiyo, A; 7:44-5 (Dec. 1969). (In Japanese). Abstract NSA 24-27214. (July 31, 1970).